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ABSTRACT

METHODS DEVELOPMENT IN BIOLOGICAL MASS SPECTROMETRY:
APPLICATION IN GLYCOPROTEOMICS
Proteomics refers to global characterization of the full set of proteins present in a
biological sample. Various analytical disciplines contribute to proteomics but mass
spectrometry became method of choice for analysis of complex protein samples.
Mass spectrometry allows for high throughput analysis of the proteome but, moreover, it
has the ability to acquire higher-order information such as post-translational
modifications (PTM). Glycosylation is the most abundant PTM on eukaryotic proteins.
This dissertation will focus on method development for structural proteomics that
will be utilized to explain the glycoproteome of obligate intracellular protozoan parasite
Toxoplasma gondii as a model system.
Optimization of sample preparation is addressed in the first part of this
dissertation. Sample preparation for mass spectrometry analysis is a critical step in the
proteomics workflow because the quality and reproducibility of sample extraction and
preparation significantly impacts the separation and identification capabilities of mass
spectrometers. Also, there are problems unique to intracellular parasites as limited
amount, host cell impurity and choice of the host. The additional obstacle is to extract
only glycosylated proteins for which there is no one standard method. Here we report the
optimal sample preparation method utilizing agarose bound Concanavalin A (Con A)
beads to efficiently pull down glycoproteins, dialyze and analyze them using MuDPIT.
This method was further enhanced by passing the non-retained protein fraction (first
flow-through) through a second Con A column and then passing the second non-retained
protein fraction (second flow-through) through the third Con A column (3 sequential
pull-downs) yielding 394 benchmark proteins.
Glycoproteome of Toxoplasma gondii is not yet fully understood. However,
evidence suggests that glycosylation could be essential for cyst formation and
maintenance which is characteristic of chronic stage of disease. The focus of the second
part of dissertation is to better understand the differences in glycoproteomes of
tachizoites and tissue cysts. Cyst proteins pulled down using optimized sample
preparation method that do not appear in the tachyzoites pulldowns could be critical
elements in the structural stability of the tissue cyst.

KEYWORDS: Mass spectrometry, glycoproteomics, lectin affinity purification,
MuDPIT, Toxoplasma gondii.
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CHAPTER 1
STATEMENT OF RESEARCH

Toxoplasma gondii is obligate intracellular protozoan parasite that causes the
disease called toxoplasmosis. This parasite undergoes three stages in its lifecycle. In the
primary host the parasite is in the stage of oocysts. Shortly upon ingestion by the
secondary host it transforms into rapidly growing tachyzoites causing the acute stage of
toxoplasmosis. Tachyzoites localize in skeletal muscle, myocardium, brain, and eyes and
develop into slow growing bradyzoites contained in tissue cysts. These cysts remain in
the host throughout the life causing the chronic toxoplasmosis.
The logical way to prevent the chronic toxoplasmosis is to prevent the cyst
formation. However, that mechanism of parasite’s transformation from the tachyzoite to
bradyzoite form and the formation of tissue cysts is yet unknown. According to current
knowledge, there is a strong indication that the differences in protein glycosylation
between tachyzoites and tissue cysts may provide a better insight into this process and,
therefore, suggest the possible ways to prevent it.
Estimates suggest that over 30% of global human population is infected and
suffers from toxoplasmosis. According to Centers for Disease Control and Prevention
(CDC), the number of infected men, women and children in the USA only is around 60
million. Currently, only palliative care can be utilized but the cure is yet to be
discovered.
Despite such a wide spread infection that sparks scientific interest, this parasite’s
weaknesses and, therefore, potential drug targets, remain largely unknown. One of the
reasons is the lack of methodologies to study the parasite. This dissertation represents the
efforts toward developing a method to study the glycoproteome of intracellular organisms
and consequently increase the knowledge base of Toxoplasma gondii.
The dissertation is organized in three main parts. The first chapter outlines the
current knowledge and background of only a relevant subset of methodologies applied in
proteomics. In addition to the definition of proteomics and bottom-up proteomics, the
discussion focuses on separation methods as well as ionization techniques, mass
1

spectrometry and data analysis. These methodologies provide valuable tools utilized to
study the glycoproteome of Toxoplasma gondii.
Second chapter describes the steps in developing the workflow to study the
glycoproteome. Methods are validated utilizing a whole cell lysate of HeLa cells as a
benchmark. The workflow is crafted by choosing the best approach for each step in the
method.
The established workflow developed in Chapter 2 is applied to study
glycoproteomes of tachyzoite and cyst form of Toxoplasma gondii is discussed in the
third chapter. Analyzing the differences between the two proteomes provides the
direction for further research that is beyond the scope of this dissertation.

Copyright@Sanja Trajkovic 2014
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CHAPTER 2
INTRODUCTION

Proteomics

Proteomics is an ever-growing set of qualitative and quantitative methodologies
used to define the structure and function of all proteins. [1, 2] Considering the role of
proteins and their interactions in cellular function, proteomics has become a leading
technology to further unravel biological processes. [3]
Various analytical disciplines contribute to proteomics but mass spectrometry
became the method of choice for analysis of complex protein samples. Three pillars of
mass spectrometry based proteomics are protein separations science, mass spectrometry
(MS) and bioinformatics. [4]
Protein separation science focuses on enrichment of a subset of proteome from a
highly complex proteome using a diverse set of strategies such as depletion of highly
abundant proteins and sample fractionation attempting to decrease sample complexity.
These strategies contribute to the overall analysis by reducing competition for ionization
and improving duty cycle thus extending dynamic range of proteins identified by mass
spectrometry.
Mass spectrometry allows for high throughput analysis of proteome but,
moreover, it has the ability to acquire higher-order information such as protein
localization, protein-protein interactions and protein post-translational modifications
(PTM). [5]
High throughput mass spectrometry generates extensive amounts of data that
would be impossible to analyze without bioinformatics tools. Utilizing various software,
organizing and analyzing overwhelming amounts of biological data becomes a swift task
enabling substantial contribution to the knowledge base.
Proteomics, as a large-scale study of proteins, can generally be divided in three
categories: structural proteomics that analyzes protein structure, functional proteomics
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that analyzes protein-protein interactions and expression profiling proteomics that
analyzes the expression of proteins.
The global analysis of expressed proteins can identify particular proteins affected
by a certain treatment or disease thus helping in drug target or biomarker discovery. This
dissertation will focus on this category utilizing structural proteomics to explain the
glycoproteome of Toxoplasma gondii as a model system.

Proteomics vs genomics

Genome refers to the genetic material of an organism including both genes and
non-coding sequences of DNA and RNA. Genome of a certain organism is the same
throughout all the cells comprising that organism. After transcription of DNA to RNA,
proteins are expressed in the process called translation. However, a large portion of the
genome will be silenced until environmental stress or other extracellular signal stimulates
the expression of a certain protein. Therefore, regardless of technique, it will not be
possible to visualize all proteins that genome can code for. [6]
While the genome is the same from cell to cell, the proteome is very different
depending on the cell type and function. Also, as a consequence to stimuli genes can
alter protein expression or transform their function. Therefore, information obtained
from genome sequencing does not depict currently expressed proteome.
Most proteins are posttranslationally modified that further contributes to
complexity. There are many types of posttranslational modifications (PTM) such as
glycosylation, phosphorylation, acetylation, methylation and many other. These
modifications usually regulate protein function and make the whole proteome very
complex and dynamic. As the name suggests, PTMs take place after translation, and
therefore, cannot be fully understood and studied at the genome level.
However, genomics provided an enormous benefit to proteomics. Those two
technologies are complementary and some scientific questions are better addressed by
one over the other approach. [3] Simply, the genome provides possibility while the
proteome is your reality.
4

Genomics alone cannot determine the nature of functional proteins. Hence,
proteomics, as a study of the proteome, is necessary to analyze the current state of any
organism, in health or disease, at molecular level.

Proteomics Strategies

Two major strategies used for protein identification are top-down and bottom-up
proteomics. The top-down approach analyzes intact proteins while bottom-up analyzes
chemically or enzymatically produced peptides. Even though the top-down strategy has
better sequence coverage and characterization of posttranslational modifications, frontend separation of intact proteins is arduous and it requires higher mass accuracy
instruments. The bottom-up approach is much more suitable for complex protein
mixtures and large-scale analysis. [1, 7] Therefore, bottom-up proteomics will be
discussed in more details.
Bottom-up proteomics is based on proteolytic digestion of proteins prior to mass
analysis. Among many available proteases trypsin is the most widely used for generating
peptides for mass spectrometry analysis. Trypsin is a serine protease that cuts the protein
sequence on the C-terminal side of lysine and arginine unless they are followed by
proline. This results in peptides with at least two protonation sites, C-terminal basic
residue and N-terminal amino group which is a minimum requirement for tandem mass
spectrometry. [4, 8-10]
Tandem mass spectrometry is a multi-stage mass analysis that provides a unique
capability to obtain structural information that can be useful in structure elucidation. It is
the key technique for protein or peptide sequencing and posttranslational modification
analysis. Collision-induced dissociation (CID) produces peptide fragments and provides
information about peptide sequence. Multiple collisions with gas atoms internally heat
the peptide cations which results in peptide bond fragmentation. However, this process
also leads to losses of water, NH3, and labile posttranslational modifications as sulfation
or nitration of tyrosine. Consequently, sequence information of large peptides is limited.
[5, 11]
5

The result of peptide sequence analysis is then searched against database of in
silico generated peptide fragmentation patterns where algorithms are utilized to
reconstruct the protein sequence. However, there is an overwhelming number of
proteolytic peptides in a sample, and only a small subset of all peptides in a sample can
be analyzed in a single MS run. Mass spectrometers only sample a small percentage of
the total number of peptides in a sample which limits the number of proteins in a sample
that can be identified. [7]
Overall, the bottom-up strategy, with good front-end separation is well suited for
large scale protein identification and analysis of posttranslational modification, therefore,
it is utilized in method development for glycoproteomics.

Separation Technologies

High Performance Liquid Chromatography (HPLC)

Prof. Csaba Horváth first mentioned the HPLC acronym in 1970 describing high
pressure liquid chromatography where high pressure of maximum 500 psi was used to
generate the flow required for liquid chromatography in packed columns. Soon after,
new pumps were developed with maximum pressure of up to 6,000 psi that together with
improved injectors, detectors, and advanced packing material gave a new name to the old
acronym, high performance liquid chromatography. [12]
Today HPLC is one of the most powerful tools in analytical chemistry with the
ability to separate, identify, and quantify compounds that are present in any sample
dissolved in a liquid.
Components of HPLC system are: injector, pump, separation column and
detector. Appropriate mixture of solvents, mobile phase, is continuously running through
the system under high pressure. After injection the analyte, now within the mobile phase,
is forced through the separation column. Column is packed with the stationary phase
comprised of small particles (3 – 10 µm) with specific residue that have different affinity
6

toward components of the passing analyte. Considering the affinity of the residue,
components of the analyte are separated by how long they are retained on the residue.
The least retained components are eluted from the column first with the short retention
time followed by strongly retained ones with the long retention time. From the column
the flow is directed toward the detector which in our case is mass spectrometer.
The choice of liquid chromatography technique depends on the type of sample.
Reversed-phase chromatography and ion exchange chromatography together with mass
spectrometry analysis are typically used for peptide separation in proteomics.

Reversed Phase (RP) Chromatography

Reversed phase liquid chromatography (Figure 2.1) is based on interaction
between the analyte within a polar mobile phase and hydrophobic stationary phase.
Nonpolar stationary phases are often made of spherical silica particles with surface
modified with hydrocarbon chains called the bonded phase. Particles are made porous in
order to increase their surface area and consequently the number of hydrocarbon chains
that will bind the analyte.
In highly polar (aqueous) mobile phase analytes bind to the stationary phase.
Using organic solvent gradient, when the non-polarity of the mobile phase matches or
exceeds non-polarity of the analyte, it will desorb from the stationary phase into the
mobile phase. Therefore, analytes are eluted in the order of increasing hydrophobicity.
Analyte interacts with the stationary phase via weak van der Waals or dispersive
interactions that are the result of overlap of the outer electron clouds between the analyte
and stationary phase.

7

Figure 2.1. Principles of reversed-phase liquid chromatography. A. Analyte bound to the
stationary phase. B. Analyte eluted from the stationary phase due to presence of organic
solvent.

Mechanism of the analyte transfer from the mobile phase to or from the stationary
phase can be explained by adsorption and desorption of the analyte from the stationary
phase. In both cases, transfer of the analyte is explained by equilibrium process of the
environment exchange, from mobile phase to stationary phase and back to mobile phase,
as described by the equation. The stage when the equilibrium has been established is
called theoretical plate height. [13, 14]
Astationary phase ↔ Amobile phase
Stationary phase is packed in the column. Properties of chromatographic column
such as retention time, resolution and selectivity depend upon particle size, pore size,
functionality and chain length of the bonded phase and column length. They also depend
on mobile phase composition, gradient profile as well as the length and internal diameter
of connecting tubing. Resolution equation explains the relationship between retention
(k), efficiency (N), and selectivity (α):

Rs =

1
α−1
k
N1/2 (
)(
)
4
α
k−1
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While the smaller particle size improve efficiency (N), retention (k) depend on
duration of the whole analysis. However, selectivity has the greatest impact on
resolution. Selectivity can be explained as the distance between adjacent peaks and it
increases with increasing distance.
Column efficiency is determined by the plate count (N) and the theoretical plate
height (H).
N=
L − length of the separation column

L
H

H − theoretical plate height
Van Deemter equation describes the relationship between the theoretical plate
height and linear velocity.

H=A+
u − linear velocity of the mobile phase

B
+ Cu
u

A − Eddy diffusion
B − longitudinal diffusion coefficient
C − resistance to mass transfer in the stationary (Cs) and mobile (Cm) phases
Eddy diffusion term (A) describes different paths analyte can have while passing
through the column and it depends on the size of particles and their uniformity.
Longitudinal diffusion term (B/u) depends on molecular diffusion in the axial
direction. Cu describes the mass transfer time needed to establish the equilibrium
between mobile and stationary phase.
The column efficiency increases with lower value of theoretical plate height.
Higher values of theoretical plate height indicated longer time to establish the equilibrium
and, therefore, broader chromatographic peaks. [15]
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Liquid Chromatography – Mass Spectrometry (LC-MS) for peptides

Peptides and proteins are usually analyzed by reversed-phase HPLC with mass
spectrometric detection. Specificity and selectivity of mass spectrometry lower
requirements for separation selectivity but put constrains on method development by
limiting the number of workable reagents.
HPLC delivers the analyte in the liquid form but mass spectrometers analyze ions
in the gas phase. One of techniques that can bridge the gap and transfer peptides to the
gas phase without degradation is electrospray ionization (ESI). This technique is affected
by the surface charge and tension, the size of the liquid drop delivered from the HPLC
system, solvent volatility and solvation strength. In turn, these parameters are affected by
the internal diameter and the length of the column and the post-column tubing, mobile
phase composition, pH, modifiers, etc. [16]
Concentration of the analyte reaching ESI at the certain moment depends on the
internal diameter of the HPLC column. Analytes are less diluted in columns with smaller
diameter thus yielding higher signal on the detector. Typical internal diameters are
between 180 and 360 µm for flow rates of 1 to 10 µL/min.
However, after the analyte exits the separation column it passes through the
connecting tubing until it reaches the ESI probe. During that time dispersion of the
analyte occurs leading to the peak broadening and decreased sensitivity. For that reason
the post-column tubing should be minimized.
Composition and properties of the mobile phase have a major impact on
ionization efficiency. The usual composition of the mobile phase for HPLC systems with
mass spectrometry detection is a mix of water and organic modifier, such as methanol or
acetonitrile, as well as ionic modifier as formic acid (pKa = 3.77) that is a preferred ionic
modifier for LC-MS systems. Ionic modifier is added to reversed-phase HPLC as an ion
pairing agent that increases retention time, prevents ionization of carboxyl groups and
protonates amine and silanol groups. [13, 17]
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The purpose of the organic modifier is to compete for the analyte against the
stationary phase. Most commonly used organic modifier is acetonitrile due to lower
surface tension of the mixture resulting in better electrospray ionization.
Peptides can carry one or more charges, on carboxylate (-COOH) and amine (NH2) groups as well as on amino acid residues. Number of charges depends on the pH of
the mobile phase and pKa value of each residue.

Strong Cation Exchange Chromatography

As stated before, peptides can carry one or more charges, on carboxylate (COOH) and amine (-NH2) groups as well as on amino acid residues. The overall charge
of the peptide depends on its amino acid sequence. Ion exchange chromatography
separates peptide on the type of their overall charge (positive or negative) and on the
relative charge strength.
The premise of ion exchange chromatography is that ions can be exchanged with
ions of the same type regardless of their mass. Ions from the solution reversibly bind to
ions of the opposite charge that are bound to the stationary phase called ion exchanger.
Desorption of the analyte depends upon ionic strength of the mobile phase. Analytes
with higher net charge require higher ionic strength to desorb. [18]
Ion exchange stationary phases are classified in two main groups: cation (separate
cations) and anion (separate anions) exchangers. Cation exchangers utilize acidic groups.
If those groups are derived from the strong acid such as sulfonic acid, they are called
strong cation exchangers. [4]
One of the factors affecting the elution is exchange capacity, or the concentration
of ion exchange groups on the surface of the particle.
Another factor to consider is the pH of the mobile phase. The analyte will not be
retained on the column unless it is ionized at the particular pH. Also, if the ion exchanger
is neutralized that site is no longer available for binding.
The nature and concentration of the salt controls its eluting strength. NH4+ is
commonly used in strong cation exchange chromatography.
11

The separation of components of complex mixtures is achieved by utilizing salt
gradients that gradually increase ionic strength of the mobile phase thus eluting
components in the order of increasing net charge (Figure 2.2). [4, 18]

Figure 2.2. Principles of the strong cation exchange liquid chromatography. A. Analyte
bound to the stationary phase. B. Analyte eluted from the stationary phase due to
presence of ions in the solution.

Multidimensional Protein Identification Technology (MuDPIT)

Regardless of the species, the whole cell lysate contains thousands of proteins.
This complex mixture is further complicated utilizing digestion to produce peptides
required for mass spectrometric analysis.
On the other hand, mass spectrometry can analyze a limited number of peptides at
any given moment. Additionally, limited duty cycle of mass spectrometers may result in
undersampling of complex proteomic samples. Low abundant peptides are at higher risk
of being lost considering that only three most abundant peptides undergo fragmentation.
For all these reasons, complex samples like whole cell lysate have to be separated
in multiple less complex samples before mass spectrometric analysis to increase the
resolution and peak capacity that are crucial to the success of the analysis.
12

Solution lies in the reduction of sample complexity which is achieved by sample
purification and fractionation. If the experiment aims to study a subset of proteins, the
complexity of the sample can be attained by removal of high abundance proteins
utilizing, for example, affinity chromatography. Fractionation of the sample based on a
certain physico-chemical property and performing multiple HPLC runs further decreases
sample complexity and reduces the number of coeluting peptides.
The most commonly used fractionation method is multidimensional protein
identification technique (MuDPIT). The strength of this method lies in combination of
two orthogonal types of separation (Figure 2.3). First, peptides are separated based on
differences in their accessible surface charges utilizing strong cation exchange (SCX)
chromatography. Peptides in each subgroup are then separated based on differences in
their hydrophobicity utilizing reversed-phase HPLC chromatography.[19]
For MuDPIT analysis strong cation exchange resin is packed in tandem to
reversed-phase C18 resin. Separation starts when strong cation exchange resin binds
positively charged peptides. Peptides are eluted off the strong cation exchange column
by increasing ionic strength of the mobile phase in a stepwise manner from low to high
salt concentration. A portion of peptides is released in each salt step depending on the
salt concentration. Those peptides proceed to reversed-phase C18 where they bind based
on their hydrophobicity. Using organic gradient, peptides are eluted off the C18 resin and
continue toward the mass spectrometer. Once the C18 resin is equilibrated back to high
aqueous conditions, the next cycle starts with the higher salt concentration. [20-23]
This method is customizable in terms that complexity of the sample dictates the
number of the salt steps and the slope of the organic gradient.
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Figure 2.3. A. Finnigan LCQ Deca ion trap mass spectrometer coupled with LC
Packings Ultimate 47 quaternary capillary LC system. B. Strong cation exchange and
reversed-phase C18 columns in series.

Separation can be done online as well as offline. In offline version, elutions from
strong cation exchange resin are collected and then injected separately. However, the
online version prevents sample loss rendering increased sensitivity and greater dynamic
range of MuDPIT analysis than some other methods, such as an offline ion exchange
approach.
However, regardless of how well is the sample separated or purified there will
always be a portion of the proteome such as low-abundant proteins, proteins with extreme
14

pI and molecular weight and membrane proteins that will be lost during sample
processing. [22][23]

Electrospray Ionization - Ion Trap Mass Spectrometry

Peptides are polar, nonvolatile and thermally unstable species that are eluted from
the liquid chromatography system in the solution, and hence incompatible with the mass
spectrometry analysis, that requires ions in the gas phase. At first glance, mass
spectrometers would not be as suitable detectors for HPLC technique as they are for gas
chromatography. However, an appropriate sample introduction technique can bridge the
gap. One of techniques that transfers peptides to the gas phase without degradation is
electrospray ionization (ESI) particularly useful for the analysis of polar compounds.
[24, 25]

Electrospray ionization (ESI) – Making Droplets

Analyte is eluted from the HPLC column in a liquid mobile phase and must be
converted into gas phase ions that can then be analyzed by the mass spectrometer.
Ionization of the analyte occurs in the solution within the charged mobile phase and the
next challenge is how to transfer it to the gas phase. Electrospray ionization (ESI) is
particularly popular because the process of gas-phase ion formation takes place at the
atmospheric pressure and allows ion formation directly from the solution. Since peptides
are not fragmented during this process ESI is considered to be a “soft ionization”
technique. This technique primarily generates molecular ions (M+), protonated molecules
([M + H]+), simple adduct ions ([M + Na]+) and ions with neutral losses ([M + H –
H2O]+).
The electrospray ionization process occurs at the ESI probe whose purpose is to
produce charged aerosol droplets that contain sample ions. The whole process involves
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three steps: 1) nebulization of sample droplets into smaller charged droplets, 2)
desolvation of droplets and 3) ion ejection.

Figure 2.4. ESI chamber, Finnigan LCQ Deca ion trap mass spectrometer.

HPLC column is directly attached to ESI probe (Figure 2.4). The sample is fed in
to a fused silica capillary that is, together with spray needle and spray nozzle, part of the
ESI probe. High positive voltage (+500 V to +4.5 kV) applied to the tip of the spray
needle induces charge separation within the drop by pulling positive charge towards the
liquid front and forming the Taylor cone. Negative charge is removed by discharge
against the metal wall of the spray needle. [26] A small highly positively charged droplet
leaves the surface of the liquid when electrostatic repulsion overcomes surface tension.
Opposite from the ESI probe is a heated capillary. Potential between the spray needle
and heated capillary drives the droplet through the surrounding gas toward the entrance to
mass analyzer through ion optics. Assisted by nitrogen gas, applied through the spray
nozzle, solvent molecules leave the droplet that in turn decreases in size. According to
ion evaporation model (IEM) the charge density at the droplet surface increases until it
reaches about 80% of the Rayleigh limit when electrostatic repulsion becomes stronger
than the surface tension and the droplet undergoes Coulomb explosion into smaller
droplets. [27-30] This process continues until droplets are so small that ions desorb into
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the gas phase and are sampled by the mass analyzer. After ejection and before they reach
the mass analyzer, ions can undergo some gas-phase reactions like proton transfer and
charge exchange. [31]
Several features affect the ESI process like solvent volatility, droplet size and
liquid surface tension. Smaller droplets are formed with lower flow rates which is
achieved with splitter. Another factor influencing qualitative and quantitative
performance of mass spectrometer is variability of analyte response known as ion
suppression. The main cause of this process is presence of less volatile compounds in a
solution phase that can change the droplet solution properties. But other processes as
precipitation and ion pairing can also be responsible for ion suppression. All these in turn
affect the droplet formation and evaporation thus affecting the amount of charged ions
reaching the detector. [17, 32]
Also, pH of the mobile phase should be chosen so it keeps the analyte charged.
Mobile phases with low pH are utilized for the analysis of basic analytes in the positive
electrospray mode. Weak acid, like formic, is added to adjust the pH while salts, strong
acids and bases are very detrimental due to solid deposits. The concentration of the
added acid should be low to avoid the competition with the analyte for the proton because
that can also decrease analyte response. [33]

The Path of Ion

Droplets created in ESI process travel toward the heated capillary that further
helps desolvation process. Temperature of the heated capillary can be anywhere from
120 °C to 350 °C depending on the flow rate, type of the analyte and the mobile phase.
Positive ions are transported through the heated capillary utilizing pressure gradient from
the atmospheric region to capillary-skimmer region (~ 1 torr) assisted by a potential of 0
to +10 V and enter the tube lens. The purpose of the tube lens is to focus ions and stop
the flow of ions into the mass analyzer during detection. Potential applied to the tube
lens focuses ions toward the opening of the skimmer. Tube lens offset voltage is
additional potential (0 to +40 V) applied during ion collection that accelerates ions that
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collide with the background gas further helping with desolvation process and thus
increasing sensitivity. However, if collisions are too energetic sensitivity decreases due
to fragmentation (ion source collision induced dissociation). Tuning procedure optimizes
sensitivity of the tube lens offset voltage. During detection of ions that already entered
mass analyzer, the voltage applied to the tube lens is -200 V thus deflecting all positive
ions away from the opening of the analyzer. [33]
Passing the skimmer, ions enter lower pressure ion optics region at 10-3 torr on
their way to mass analyzer. Ion optics have three parts: quadrupole, octapole and
interoctapole lens. Electric field made of RF (2.45 MHz, 400 V) and dc offset voltage (10 to +10 V) applied in this region guides and focuses ions that are now entering the
vacuum region of the mass analyzer. [33]

Figure 2.5. Electrospray ionization (ESI) process.

Mass Analyzer - Ion Trap

The heart of every mass spectrometer is mass analyzer where ions are separated
based on their mass to charge ratios (m/z) and sent to the detector. There are four general
types of mass analyzers: quadrupole, time of flight, sector and ion trap. Our instrument is
equipped with ion trap that will be the focus of further discussion.
An ion trap consists of three stainless steel electrodes, two end-caps and one ring
electrode, of hyperbolical geometry (Figure 2.6). They together form the cavity with
dimensions of r0 and z0 as shown in the picture. Both end caps have holes in their centers
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where ions enter the cavity of the ion trap and exit through the opposite end cap after they
have been separated according to their mass to charge ratio. [31]

Figure 2.6. Ion trap elements: two end-caps and one ring electrode.

As the name says, an ion trap mass analyzer traps ions in a three dimensional
electric field. Ions are stored, separated according to their mass to charge ratio and then
selectively ejected which increases the sensitivity of the device. [34]
Gating lens controls the entry of the ions into the trap. Negative potential is
applied to it to enable positive ions to enter the trap. The time of ion accumulation is
optimized to allow for maximal signal and minimal space charge. Excess ions in the trap
are detrimental due to changes in electrical fields they cause, while too few ions lead to
loss of sensitivity. Once the optimal amount of ions entered the trap the potential on the
gating lens is changed to positive to prevent further entrance of positive ions. Ion trap
can analyze negative ions as well. In that case the potential applied to the gating lens is
reversed. [35]
Inside the ion trap RF oscillating potential is applied to the ring electrode and
focuses ions to the center of the trap. Ions move in complex pattern and high kinetic
energy. Damping gas (helium, 1 mTorr) is used to prevent the premature ejection by
colliding with the ions and reducing their kinetic energy. This results in focusing ions
toward the center of the trap. [33, 35]
Potential applied to the ions in the ion trap is described by the following equation:

Φr,z

( U − V cos Ωt) r 2 − 2z 2
( U − V cos Ωt)
=
�
�
+
2
2
r02
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U – dc potential
V – Rf amplitude applied to ring electrode
Ω − angular frequency of RF (V), typically 1.1 MHz
r0 – internal radius the ring electrode
r – distance between the ion and the ring electrode
z – distance between the ion and the end-cap electrode

Solutions are given by the second order differential equation named the Mathieu
equation. Ion stability in the ion trap is described with two dimensionless Mathieu
parameters az and qz,

qz =
az =

2eV
mr02 Ω2

4eU
mr02 Ω2

Dimensions of the ion trap, angular frequency of RF potential, mass and charge of
the ions are constant values. Therefore, dc potential (U) and RF amplitude (V) control
ion’s motion described by the solutions of Mathieu’s equation or graphically presented
with the plot of az vs. qz named Mathieu stability diagram (Figure 2.7). [36] There are
two types of solutions of Mathieu’s equation:
a)

Periodic and unstable – describe boundaries of unstable region of

the stability diagram,
b)

Periodic and stable – describe motion of ions within the ion trap.

Ions are trapped if the intersection of az and qz falls within boundaries of the
stability diagram. However, if the intersection value falls outside of boundaries of the
stability diagram, the ion is ejected.
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Figure 2.7. Mathieu stability diagram for a 3D quadrupole ion trap

In commercial ion traps dc voltage is constant and set to give radial stability to all
ions. Their stability and ejection is controlled in the axial direction.
When dc voltage is set to zero stability diagram collapses to qz axis and ion trap
operates in the “mass selective instability scan” mode. Rising RF potential applied to the
ring electrode moves the ions along the qz axis. Stable ion trajectories have the qz value
between 0 and 0.908. As the qz value approaches 0.908, ions gain the kinetic energy,
reach the boundary of the stability diagram, become unstable and are ejected from the ion
trap through holes in the end-cap. This is the low-mass cutoff limit. Mass selective
instability scan mode of operation generates the full scan mass spectrum by sequentially
ejecting ions from low m/z to high m/z. [31, 35] However, this approach does not allow
the selection of ions.
Resonance ejection is one of the methods for ion selection that induces instability
of a particular ion utilizing ac voltage of high amplitude or supplementary RF potential
on the end-caps that changes secular frequency of the ion resulting in its ejection.
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An alternative method is axial modulation where RF frequency is constant but the
amplitude is ramped which can selectively eject several or all ions.
After ejection, ions are accelerated by the conversion dynode and sent to the
channel electron multiplier for detection. [31] The number of ions reaching the detector
depend on ESI efficiency, ion sampling efficiency into the vacuum and ion transmission
efficiency through ion optics and the ion trap. [27]

Tandem Mass Spectrometry

Tandem mass spectrometry (MS/MS) is a multiple stage mass spectrometry that
acquires data in a data dependent mode. One of the advantages of an ion trap mass
analyzer is the ability to perform tandem mass spectrometry in time without the need for
an additional mass analyzer.
The first step in data-dependent mode is to acquire a full scan mass spectra.
When one of the ions reaches signal threshold, it is isolated by applying the appropriate
RF wave form that will eject all other ions. Then, “tickle” potential is applied across the
end-caps to resonantly excite the ion of interest. This is similar to axial modulation.
However, the amplitude of “tickle” potential is chosen in such manner not to eject the ion
but to pull it away from the center of the trap. Ion gains energy from the RF drive
potential and collides with helium experiencing collision induced dissociation (CID).
Resulting fragments are analyzed by increasing amplitude of RF potential and ejected
from low m/z to high m/z. After obtaining the MS/MS spectrum analyzed ion is put on
the exclusion list and not analyzed during selected time frame regardless of the signal
intensity. During that time the ion trap fills again with all ions and instrument analyzes
other ions that reached signal threshold.
To enhance the statistics three micro-scans are averaged to generate the data
dependent full scan spectrum. Three most intense ions are then subjected to tandem mass
spectrometry with five spectra averaged to produce one MS/MS spectrum.
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Bioinformatics for Proteomics

CID of the peptide cleaves the amide bond and generates fragments characteristic
of the specific amino acid sequence (Figure 2.8). Charge can be retained on N-terminus
yielding a, b and c ions or on C-terminus yielding x, y and z.[37] However, b and y ions
are most abundant when low energy CID is employed.

Figure 2.8. Peptide fragmentation notation.

The first step in proteomic data processing is to assign the spectrum of a fragment
to a primary protein sequence. To accomplish that an overwhelming number of
computational approaches and tools have been developed. [38] In general, experimental
mass values are compared with calculated peptide masses and fragment ion mass values.
Calculated masses are obtained when the set of cleavage rules is applied to the protein
primary sequence database. Scoring algorithms are used to identify the closest matches
thus identifying the unknown protein from the sample. Considering proteomes of
different species are not yet fully elucidated if the sequence database does not contain the
unknown protein then the algorithm matches it to the protein of the closest homology.
[39]
Mascot is a powerful search engine that provides search method for MS/MS ion
search, and therefore, is utilized for the purpose of qualitative proteomics.
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Mascot search engine converts MS/MS spectra into mascot generic format
(MGF), which is a list of pairs of mass and intensity values. MGF files are searched
against the database of calculated peptide or fragment ion masses. [40]
A set of search parameters, such as choice of proteolytic enzyme, number of
missed cleavages, peptide mass tolerance, choice of search masses and protein molecular
weight, provide versatility and the ability to identify proteins with maximum
discrimination and the highest score.
Mascot search engine is based on Mowse algorithm but it also adds probabilitybased algorithm. [41] Proteins are identified based on the probability (P) that the match
between the experimental data and theoretical value is a random event giving the lowest
probability to the best match. The score is calculated using the equation below.
score = −10 × log10 P
These values are converted into Mowse scores assigning the highest score to the
best match. [42]
Mowse (MOlecular Weight SEarch) method identifies the proteins based on
molecular weight of their respective peptides measured by mass spectrometry. To
achieve that, experimental data are first compared with calculated peptide masses in the
sequence database and only entries that fall within a given mass tolerance are accepted as
a match. Each match is assigned a statistical weight that is determined utilizing empirical
factors such as frequency (F).
A frequency is calculated using matrices where intervals of 100 Da of peptide
mass were put in the rows (i) and intervals of 10 kDa of intact protein mass were put in
columns (j). Each experimentally obtained ion falls into the appropriate matrix element
fi,j. The frequency of occurrence gives the size distribution of peptide masses as a
function of protein mass. The frequency is normalized by dividing the elements of each
10 kDa column by the largest value in that column. This process gives the factor m
according to the equation below.
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mi,j =

fi,j

fi,j

max in column j

Factors m for each entry are then multiplied (∏n mi,j) and used together with the

molecular weight of the entry (MWprot) to calculate the score utilizing the following
equation
score =

50,000
MWprot × ∏n mi,j

Copyright@Sanja Trajkovic 2014
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CHAPTER 3
SAMPLE PREPARATION FOR MASS SPECTROMETRY OF GLYCOPROTEINS

Following translation, the next step in protein biosynthesis are various
posttranslational modifications (PTM) such as glycosylation, methylation,
phosphorylation and many others. Considering the critical role of PTMs as regulators of
protein activity and function it is essential to expand the current body of knowledge on
this topic. However, very low levels of PTMs within complex biological system poses an
impediment to researchers. Therefore, development of new enrichment techniques are
necessary to prevail in this challenge.
The purpose of this chapter of dissertation is to describe the effort put to develop
the new technique for enrichment of glycoproteins from the complex matrix such as
whole cell lysate.

Posttranslational modifications of proteins

Posttranslational modifications (PTM) are ubiquitous and denote the attachment
of various functional groups or structural changes of the proteins after translation further
diversifying protein structure beyond what is acquired by gene transcription. These
modifications play a key role in many biological events like gene expression, signal
transduction, protein-protein interaction and many more because they regulate protein
activity by changing its surface or introducing new functional groups. In turn, this
changes thermodynamic and kinetic features of proteins as folding rate and stability. [43,
44]
There are many PTMs such as glycosylation, phosphorylation, methylation,
ubiquitination, lipidation, nitrosylation, acetylation and proteolysis. Glycosylation has
been recognized as one of the major PTMs. [44] Since glycoproteins are the central
theme of this dissertation glycosylation is discussed in more details.
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Protein Glycosylation

In general, glycosylation is the process of covalent binding of glycans and
proteins catalyzed by a series of enzymes. Glycosylation can be discussed from the
perspective of protein or of glycan. From the protein perspective, benefits of
glycosylation are enhanced thermal stability and folding kinetics of the protein, increased
solubility and resistance to proteolysis. Also, the process of glycosylation itself depends
on the number, location and surroundings of the glycosylation sites on the protein. [45]
From the glycan perspective, properties of the protein depend on the size of the glycan,
its flexibility and structure. [43, 45]
The formation of the bond between a saccharide and the amino acid is the first
step in biosynthesis of glycan parts of glycoproteins. This bond initiates a series of
enzymatic steps that yield an elaborate oligosaccharide structures on the protein. It is
known up today that 13 monosaccharides and 8 amino acids are involved in at least 41
glycoprotein linkages divided in the following five types of glycosylation:
1. O-linked glycosylation – through hydroxyl oxygen of serine, threonine or
tyrosine,
2. N-linked glycosylation – through nitrogen of asparagine side chain if in the
sequence N-X-(S/T) as standard consensus sequence or N-X-C, N-G and N-X-V
as non-standard consensus sequences, where X cannot be proline,
3. C-linked mannosylation – mannose linked to the tryptophan side chain if in the
W-X-X-W consensus sequence,
4. glypiation – through glycosylphosphatidylinositol (GPI) anchor that links proteins
and lipids.
5. phosphoglycosylation – mannose, fucose, xylose or N-acetyl-D-glucosamine
linked to serine. [46]

Sites of glycosylation vary throughout the cell and include Golgi complex,
endoplasmatic reticulum, nucleus and cytosol. [47] However, the most abundant
glycosylations in eukaryotic proteins are N-linked and O-linked protein glycosylations
and they take place in cytoplasm, endoplasmic reticulum (ER) and the Golgi complex.
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Large part of the proteome of the cell is synthesized and folded in endoplasmatic
reticulum (ER) and then transported to the Golgi complex following a conventional ER–
Golgi secretory route. One of the key functions of the ER is production of glycans.
Mannose rich glycans are synthesized on the cytosolic face of the ER. These precursors
are then moved into the lumen of ER where they are further branched by adding more
mannose and glucose. While within ER precursor glycans are transferred to the
asparagine residue onto still unfolded protein by glycosyltransferases thus forming Nlinked precursor glycans. Once they reach Golgi complex, glycans are edited by
glycosidases to form mature N-linked glycans. O-linked glycosylation happens during
passage through the Golgi complex. [44, 48-52]
After translation, newly synthetized proteins are transported from endoplasmatic
reticulum to Golgi complex. Along this path they are modified by the attachment of
variety of different functional groups such as carbohydrates and lipids. These groups
change the structure and properties of proteins reversibly or irreversibly. [44, 47]
Golgi complex and endoplasmatic reticulum are not the only places where
posttranslational modifications happen, however, those are sites of glycosylation.

Glycans

According to the IUPAC Gold book, glycans are defined as "compounds
consisting of a large number of monosaccharides linked glycosidically". [53]
Glycosidic bond is the bond between the hemiacetal group of the saccharide and
hydroxyl or amine group of another organic molecule (Figure 3.1).
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Figure 3.1. Example of α-glycosidic bond.
Glycans are built from 9 different monosaccharides joined together with
glycosidic bond to form oligosaccharides (2 – 20 monosaccharides) or polysaccharides
(20 < monosaccharides). Structures of polysaccharides are more complex than proteins
since they can form various topologies. They contribute to protein diversity not only
between different organisms but different glycans can also be present on one type of the
protein. Even microheterogenious glycans that differ in the structure of only one or more
of its monosaccharides can greatly alter thermodynamic properties of a certain protein.
[54]
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Table 3.1. Glycan building monosaccharides.
Haworth
Monosaccharide

projection

Abbreviation

D-glucose

Glc

D-Glucuronic acid

GlcA

D-Xylose

Xyl

L-Fucose

Fuc

N-acetylneuraminic acid

NeuAc

D-Mannose

Man

D-Galactose

Gal

N-acetyl-D-glucosamine

GlcNAc

N-acetyl-D-galactosamine

GalNAc

Symbol

Both N- and O- linkages are through N-acetylglucosamine. However, N-linked
glycans are bonded to asparagine, while O-linked glycans to serine or threonine. Unlike
O-linked glycans, N-linked glycans have standard and non-standard consensus sequence.
The standard consensus sequence involves three amino acids. It starts with asparagine
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linked to any amino acid but proline and ends with serine or threonine (N–X–(S/T)).
Additionally, there are two non-standard consensus sequences: asparagine – X – cysteine
(N–X–C) and asparagine – X – valine (N–X–V) where X cannot be proline also. [46]

Figure 3.2. The core sequence of N-linked glycans.

All N-linked glycans have the same core sequence as shown in the (Figure 3.2).
They are divided into three classes according to the monosaccharides attached to the core
structure:
1. Oligomannose – only mannose residues attached,
2. Complex – each branch starts with N-acetylglucosamine (GlcNAc) and develops
further,
3. Hybrid – only mannose residues are attached to one of the core’s branches and the
variety of monosaccharides on the other. [55]

O-linked glycans are covalently attached to hydroxyl group of serine or threonine
by an O-glycosidic bond. There are several types of O-linked glycans:
1. O-N-acetylgalactosamine (O-GalNAc) – starts with N-acetylgalactosamine
followed by galactose, N-acetylglucosamine, fucose, or sialic acid, but not
mannose, glucose, or xylose,
2. O-fucose – that can be elongated to a tetrasaccharide,
3. O-glucose – typically exists as trisaccharide comprised of glucose and two
xyloses, although it is also found as a monosaccharide,
4. O-N-acetylglucosamine (O-GlcNAc) – starts with N-acetylglucosamine,
5. O-mannose – very complex structures and common to both prokaryotes and
eukaryotes. [56]
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Lectins

Lectins are saccharide binding proteins ubiquitous across all species. They also
may have saccharides on their surface, which classifies them as glycoproteins, but what
defines them as lectins is their ability to bind saccharides.
Lectins’ major role is to facilitate cell to cell contact. This contact is provided by
interaction of lectin displayed on the surface of one cell with saccharide displayed on the
surface of another cell. A molecule of lectin usually has more than one saccharide
binding sites. Each site forms a weak bond with the saccharide, however, synergistic
effect of multiple binding sites provides a strong interaction. [51]
There are two types of interactions between lectin and saccharide. First type is
when lectin with two binding sites binds two ligands. These complexes are linear and
flexible and ligands can vary in structure. The second type is formed when either lectin
or ligand has more than two binding sites yielding complex, cross-linked structures. The
ligand composition in this case has to be the same to be able to form the lattice. [30, 5759]
Lectins can be used for the purpose of studying the glycoproteome for substantial
reduction of the sample complexity. They are utilized for the extraction of glycoproteins
from the whole cell lysate for the affinity chromatography technique.
Concanavalin A (Con A) is one of the most widely used lectins. Perhaps one of
the reasons is its low affinity toward non-glycosylated proteins.
Con A was used for the development and conformation of the method described
in this dissertation to extract glycoproteins from the whole cell lysate of HeLa cells
(benchmark) as well as from whole cell lysate of tachyzoites and tissue cysts of
Toxoplasma gondii. For that reason Con A is discussed in more details.

Concanavalin A (Con A)
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Concanavalin A (Con A) is a lectin isolated from jack bean Canavalia ensiformis.
At pH 7.5 Con A is a tetramer but at the pH 5 and lower it reversibly dissociates in to
dimers. Each subunit is comprised of 237 amino acids and has a molecular weight of 26
kDa. They fold in the formation of two β sheets that create β sandwich. [60]
Also, each subunit has one saccharide binding site and two metal binding sites:
one for a transition metal ion and one for calcium ion. If metal ions are removed in
acidic conditions Con A can no longer bind saccharides. However, replenishing metal
ions at the pH 7 restores saccharide-binding activity. This proves that the role of metal
ions is to pull the amino acid residues into proper conformation required for binding.
[61-63]
ConA binds α-mannose and α-glucose sugars and N-glycans but it does not bind
O-glycans on animal cell glycoproteins. The binding affinity is much higher for
oligomannose-type N-glycans than complex-type biantennary N-glycans, while it does
not bind highly branched complex-type N-glycans. Examples of glycans that Con A
binds are shown in the Figure 3.3. Circled portions of glycans are required for binding.
[64]

Figure 3.3. Example of glycans that Con A binds. The parts of the glycan required for
binding are in the box.

Once Con A binds a glycan and after the purification procedure, it is important to
select a competitive inhibitor that will provide elution of the glycoproteins. Therefore, it
is important to understand the mechanism of binding.
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Con A binds the saccharide by forming hydrogen bonds with almost all hydroxyl
groups on the saccharide. The strongest bond is formed with D-mannose, then Dfructose and lastly D-glucose which still contains at least a part of configuration required
for binding.
Con A binds the saccharide in the chair conformation with C4 deepest in the
binding site and C1 closest to the surface. Hydroxyl group on C1 is extending into the
solvent and is not essential for binding with the protein, while the one on C2 has some
influence on binding which is proved by the higher affinity of binding of D-mannose than
D-glucose. It seems that in D-mannose C2 hydroxyl group better approaches the surface
of the protein. However, hydroxyl groups on C3, C4 and C6 stabilize the conformation
through hydrogen bonding with the protein and are essential for binding.
The type of the bond and the substituents also play a role in the binding affinity.
Con A has much higher affinity for α glycosidic bond than β glycosidic bond.
Additionally, substituting hydrogen for the methyl group in α-methyl glycosidic bond
increases affinity several fold. As a consequence, methyl-α-D-mannopyranoside is the
best binding inhibitor than any other saccharide, followed by methyl-α-Dglycopyranoside (Figure 3.4). [30, 64]

Figure 3.4. A. D-mannose, B. D-glucose, C. methyl-α-D-mannoside and D. methyl-α-Dglycoside, Haworth projection.

For the purpose of this project we utilized Con A for the separation of
glycoproteins from the whole cell lysis.
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Lectin Affinity Chromatography

Affinity chromatography is based on specific interaction between ligand
chemically bound to the solid support and the target molecule that is most often a
biological molecule (Figure 3.5). Therefore, molecules are separated based on their
biospecific binding to the immobilized ligand. The principle of affinity chromatography
is shown in the figure below.

Figure 3.5. Affinity chromatography principle. A. Ligand binds the glycoprotein. B.
Elution of the glycoprotein utilizing saccharide as a competing ligand.

Fundamental principles of binding are based on hydrophobicity and ion-ion
interactions as for the other types of chromatography but also hydrogen bond formation.
The difference is in biospecificity. There is usually more than one binding site on both
ligand and target molecule but they are arranged in unique orientation so they fit as lock
and key. Similar but less specific molecules can have structure that fits closely and they
will form a weaker bond with the immobilized ligand. [65, 66]
Due to biospecificity, the process of protein separation and purification has to be
optimized for each ligand and the target molecule but there are some general rules
applicable to all affinity chromatography procedures. For example, there is a limited
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number of buffer systems that can be used in order to preserve the binding properties of
the immobilized ligand. Also, detergents, pH and salt concentration are crucial for
successful binding event.
The outcome of affinity chromatography depends on several factors like ligand
selectivity, ligand stability, recovery, etc. Ligand stability determines durability and
versatility of the method. If, for example, the ligand is stable in different buffer systems
and under the wide pH range, the method will allow for more options on sample
preparation side. Recovery is determined by the amount of the target molecule efficiently
eluted from the immobilized ligand. However, ligand selectivity is perhaps the most
important factor that determines efficient separation and purification. The immobilized
ligand is also a protein with its specific amino acid sequence folded in the specific 3D
structure. The actual site of affinity binding is the binding pocket of that protein. Only
the molecules that can at least loosely fit into the binding pocket will be retained and
separated from the matrix.

Cell disruption and Protein Solubilization

In a biological system, proteins are found within the cell, at the cell membrane as
well as in the extracellular space. To that end, cell disruption is a first step in analysis of
the whole proteome inevitable to access all proteins. Cells can be disrupted chemically,
utilizing buffers with various combinations of detergents, or mechanically, utilizing
ultrasonication, homogenization or mechanical shearing.
Buffers, as radioimmunoprecipitation assay (RIPA) and nonidet P40, have been
used for the lysis of Toxoplasma gondii and subsequent lectin pull-down. [66] However,
those detergents pose the risk of decreased lectin viability or even denaturation. [67]
Alternative option is mechanical shearing of cells passing them through a narrow
valve under high pressure in the buffer with no detergents added. This process disrupts
the membrane of the cells but detergents are still required to release membrane- or
cytoskeleton- bound proteins.
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A natural surroundings of a native protein even in the whole cell lysate is a very
complex matrix material composed of other proteins, lipids, carbohydrates, salts and
other biological macromolecules. Also, proteins are often parts of protein complexes or
integrated into organelles or plasma membranes and generally insoluble in their native
state. Therefore, they have to be denatured to solubilize which means the disruption of
all disulfide, hydrogen, dipole-dipole and van der Waals bonds as well as electrostatic
and hydrophobic interactions. This is achieved by addition of salts, charged detergents,
chaotropes, and reduction and alkylation reagents to lysis buffers. However, they are
very different in their ability to disrupt cells and solubilize proteins and often are used
together. Criteria to consider when choosing the lysis buffer: pH, ionic strength,
detergents and denaturants, proteolysis preventers and protein stability enhancers. [68]
Ionic detergents, like SDS, contain a head group with either positive or negative
charge and are useful for breaking protein-protein interactions. Micelle size is
determined by combining the repulsion of the ionic head group with the hydrophobic
attraction of the side chain. The size can increase if the charge on the head group is
neutralized. Therefore, increasing ionic strength of the solution reduces critical micelle
concentration (CMC), but temperature change has no effect.
Non-ionic detergents, like triton X-100, have uncharged hydrophilic group and
are used for breaking lipid-protein or lipid-lipid interactions. They gently solubilize
proteins, retaining their native structure and function. Unlike ionic detergent, critical
micelle concentration of non-ionic detergent increases with increased temperature but
ionic strength of the solution has no effect.
Zwitterionic detergents, like CHAPS, combine properties of both ionic and nonionic detergents. They are best used for breaking protein-protein interactions. [69, 70]
For all of these reasons, when the downstream processing can tolerate the
presence of detergents, the best approach is to utilize the strengths of both mechanical
and chemical cell disruption.

Protein Purification Techniques
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After elution from the Con A column, proteins are obtained in an elution buffer
whose composition may not be compatible with the next step of the sample preparation.
For that reason, two most widely used techniques for protein purification, gel
electrophoresis and dialysis, are discussed below.

Gel Electrophoresis

Ever since its introduction in late 1950’ the polyacrylamide gel electrophoresis
technique (PAGE) is the most widely used method and the golden standard for separation
and analysis of protein mixtures as well as buffer exchange. The premise of this
separation technique is that proteins with different molecular weights and the same
charge will assume different electrophoretic motilities. However, proteins are vastly
diverse with respect to charge as well as 3D structure. To accomplish separation based
solely on molecular weight differences, they have to be denatured and saturated with the
charge which is achieved utilizing sodium dodecyl sulfate (SDS).
As an anionic detergent, SDS binds with its hydrophobic tail to hydrophobic
portions of a protein in a proportion of one SDS anion for every two amino acids. The
specific mass ratio is 1.4:1. This yields an equal charge density per unit length and
disrupts the three dimensional structure of the protein. The polar head of this detergent
interacts with the hydrophilic solution and allows the protein to exist stably in solution in
its extended conformation. The outcome of this interaction are denatured and highly
negatively charged proteins whose migration is not determined by intrinsic charge but by
molecular weight. [71] [69]
In the electric field, applied across the polyacrylamide gel, negatively charged
SDS-protein complexes move from cathode to anode. Since they are introduced to the
polyacrylamide gel from the cathode side they are forced to move through pores of the
gel. The rate at which they travel through the gel depends on the strength of the field,
size and shape of the SDS-protein complex. However, these are not the only
determinants in this technique. Solvent, with its temperature and ionic strength, as well
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as pH and the counterions with their shielding effect can greatly impact the separation.
[71, 72]
Polyacrylamide gel is obtained by polymerization of the acrylamide monomer
into long chains and crosslinked with N,N’-methylene-bis-acrylamide (bis) into threedimensional structures. Polymerization starts with the addition of ammonium persulfate
(APS) and the base N,N,N’,N’-tetramethylenediamine (TEMED) that catalyzes the
decomposition of persulfate ion to produce a free radical. This free radical then reacts
with the acrylamide monomer transferring the charge to each subsequent monomer upon
binding thus creating a linear polymer. The occasional bis-acrylamide crosslinks the
linear polymers creating the sieve-like network whose pore sizes depend on
concentrations of monomer and the crosslinker. [71, 72]
The final gel used for protein separation is a composite of two polyacrylamide
gels, stacking and resolving that differ in the pore size and pH. Sample is loaded onto
the stacking gel that has larger pore size and pH of 6.8. The purpose of this portion of the
gel is to focus all proteins into an infinitely thin band before they enter the resolving gel.
This process utilizes negatively charged chloride and glycine ions from the buffer whose
pH is 8.3.
Chloride ions create the cloud around the proteins preventing proteins to see the
field. As the chloride ions move through the gel fast, the proteins further from the
entrance to the resolving gel lose chloride ions earlier than the proteins closer to the
resolving gel and start to move toward the anode
Glycine is a weak acid and, therefore, exists as a zwitterion at low pH glycinate
anion at high pH. Once the electric field is established, glycine moves from the buffer
(pH 8.3) to the stacking gel (pH 6.8) towards the anode. The decrease of pH in the
stacking gel causes the loss of a portion of the charge on glycine that, consequently,
moves slower. The zone between chloride and glycine ions creates a high strength field
that contains all proteins. This very thin band moves in this arrangement toward the
resolving gel. Once the glycine reaches the resolving gel the increase of pH causes it to
move faster and it outruns the proteins allowing them to see the electric field.
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As the result of this process all proteins are focused at the interface of stacking
and resolving portion of the gel providing separation within the resolving gel based only
on their mass differences.
Once the negatively charged proteins reach the resolving gel they are driven by
the electric field. However, smaller proteins move faster while the larger proteins have
more difficulty moving through the pores of the gel. That is the basic principle of protein
separation on the polyacrylamide gel. [71]
SDS polyacrylamide gel electrophoresis (SDS-PAGE) can be utilized for
separation as well as purification and concentration. For separation purposes the gel is
usually cast between two 7 x 8 cm glass plates separated by 0.5 to 1.5 mm spacer.
Looking from the top of the gel the stacking portion is about 3 cm long followed by about
5 cm of the resolving gel where the separation takes place. However, the benefits of the
protein stacking process can be used as a buffer exchanger to purify the sample of buffer
components incompatible with the downstream analysis and to concentrate the proteins
into finite band. This technique is called three-layer sandwich gel electrophoresis and
requires different layout of the gel.

Three-Layer Sandwich Gel Electrophoresis

The buffers required for sample preparation and extraction from the cell culture
are incompatible with the downstream mass spectrometry analysis. Also, sample loss and
dilution becomes a significant factor when multiple preparation steps are involved.
Three-layer sandwich gel electrophoresis (TSGE) is developed with the purpose to
concentrate the proteins and to serve as a buffer exchanger thus increasing the efficiency
of the proteomic analysis.
TSGE protocol combines the properties of agarose and polyacrylamide gels. As
the name says, the gel is comprised of three parts. On the bottom of the cylindrical
cartridge is 40 % polyacrylamide gel (~ 0.5 cm) that serves as a sealing layer. It is
covered with the 12 % polyacrylamide gel (~ 2 mm) where the proteins are concentrated.
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The top layer is made of 2% agarose gel (~ 3 cm) that is used to immobilize the proteins
from the sample.
The combination of pH throughout the gel plays a significant role in concentrating
the proteins. The pH ranges from 8.3 in the running buffer through around 7 in agarose
gel and 6.8 in the concentration layer to 11 in the sealing layer.
When the current is applied these pH changes influence glycine present in running
buffer as well as all three layers of the gel. When glycinate ions enter the agarose gel
from the running buffer, they lose a portion of charge and move slower. On the other
hand, chloride anions move rapidly toward the anode. This creates the zone of high field
that contains the proteins and move toward the anode reaching the concentration portion
of the gel as a narrow band. At the interface of concentration and sealing layer the pH
changes from 6.8 to 11 that results in increase of negative charge on glycinate ions that
now move rapidly toward anode leaving the proteins out of high strength field. Facing
the very small pores of a sealing layer, proteins are stopped and accumulate at the
interface of the concentration and sealing layer.
After overnight electrophoresis, the whole structure can be pushed out of the
cartridge to access the concentration layer and prepare it for in-gel digestion. [73]
In comparison with other purification techniques TSGE proved to significantly
improve the protein recoveries and the downstream analysis. [73] However, this method
was tested on buffers containing high concentrations of salts and detergents but not on the
buffers that contain high concentrations of sugar as elution buffers utilized in lectin
affinity chromatography.

Dialysis

Dialysis is one of the most widely used methods for sample purification and
buffer exchange by removal of low molecular weight contaminants or solution
components.
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The separation is driven by concentration gradient. It is spontaneous separation
process in solution, based on the diffusion through a semipermeable membrane with the
definite pore size allowing only the molecules smaller than the pores to pass through.
In practice, the two solutions are placed in two different compartments separated
only by a semipermeable membrane. The membrane has a definite pore size and only
molecules below a certain molecular weight can pass through, defining the molecular
weight cutoff limit (MWCO). The molecules below MWCO can freely pass through the
membrane in both directions while larger molecules are retained. The solution
containing the analyte of interest and undesired small molecules is in several orders of
magnitude smaller volume than the target buffer solution. The purpose of such a
difference in volume is to maintain the concentration gradient. Due to the concentration
gradient across the membrane molecules diffuse from regions of high concentration to
regions of low concentration.
Also, the target buffer is stirred in order to increase the diffusion rate. After
entering the low concentration buffer the small molecules form a Nernst diffusion layer
where their concentration is higher in comparison with the bulk volume of the target
buffer. This slows down the dialysis due to low local concentration gradient. However,
stirring efficiently overcomes this obstacle and maintains high concentration gradient.
[74]
The diffusion phenomenon is governed by the Fick’s law:

J = −D
mol

J – diffusion flux [m2 ∙s],

D – diffusion coefficient or diffusivity [
mol

ϕ – concentration [ m3 ], and
x – position [m].
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∂ϕ
∂x
m2
s

],

Diffusion flux (J) is the measure of the amount of substance passing through the
unit area per unit time and depends on the diffusion coefficient and the concentration
gradient.

Diffusion coefficient (D) is given by Stokes–Einstein equation:

D=

kBT
6πηr
J

kB – Boltzman’s constant 1.38 x 10-23 [K],
T – absolute temperature [K],
η – viscosity, and
r – radius of spherical particle.

D is directly proportional to the temperature but inversely proportional to
viscosity of the fluid and the size of the particles. For biological molecules 10-11 < D <
10-10 m2/s.
As the concentration gradient (∂ϕ/ ∂x) decreases over time, the system reaches

equilibrium and concentrations of small molecules in both compartments become equal.
However, this is avoided by frequent change of the target buffer replenishing the system
with the new target buffer that is free of the undesired molecules.
Therefore, the best diffusion is achieved in solutions with high concentration
gradient, for small molecules in low density solutions at higher temperatures. [74]
Dialysis is a simple, low cost technique that depends on several factors as the time
required for buffer exchange, membrane chemistry and its morphological properties as
well as the shape of the protein molecules that should not be exchanged between the two
compartments. [75]
Time required to complete the buffer exchange depends on the membrane area
and temperature. Larger areas will allow for faster exchange but will also increase the
loss of protein due to adsorption on the membrane. The increase in temperature will lead
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to the faster transport through the membrane due to increased motion of molecules but
can also degrade the sample. [75]
Also, considering that buffer molecules can go through the membrane in both
directions dialysis can increase the sample volume thus diluting it. For that reason, the
samples with low protein concentrations but high salt and detergent concentrations can
experience significant sample dilution. This can partially be avoided by stepwise
dialysis, where the initial target buffer contains a certain amount of the salt and detergent
to decrease the concentration gradient and prevent the sample dilution. [75]
Even though the mechanism of the dialysis remains the same, the technique is
significantly improved. The enhanced membrane morphology provides reduced protein
adsorption and consequential loss. Also, the commercially available systems allow for a
wide range of sample volume and convenience for sample handling. [75]

Glycosylation of the proteins has been recognized as one of the major
posttranslational modifications responsible for regulation of protein function. But better
understanding of processes involving glycoproteins is hampered due to low abundance of
glycoproteins in the biological systems. The techniques described in the introductory
portion of this chapter are tested in attempt to find the best approach for isolation and
high yield of glycoproteins.
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Experimental

Materials

Neurotensin and vasopressin peptide standards were purchased from SigmaAldrich (St. Louis, MO).
Tris base, SDS, acrylamide, N,N-methylene-bis-acrylamide (Bis), Laemmli
sample buffer, ammonium persulfate (APS), N,N,N,N-tetramethylethylenediamine
(TEMED), glycine, agarose and Coomassie Brilliant Blue G-250 were obtained from
BioRad (Hercules, CA).
Trypsin-EDTA (phenol red, 0.05 %) was obtained from Life Technologies (Grand
Island, NY). Protease inhibitor cOmplete was purchased from Roche Diagnostics
(Indianapolis, IN).
Slide-A-Lyzer MINI Dialysis Device, 3.5K MWCO, 2mL and bicinchoninic acid
assay (BCA) were purchased from Thermo Scientific (Rockford, IL). Agarose bound
Concanavalin A (Con A) resin, mannose-BSA, glucose-BSA and glycoprotein eluting
solution for mannose- and glucose-binding lectins were purchased from Vector
Laboratories (Burlingame, CA).
Ammonium bicarbonate, ammonium citrate, formic acid, methanol, Optima grade
acetonitrile, Optima grade water, calcium chloride dehydrate and manganese chloride
tetrahydrate were purchased from Fisher Scientific (Chicago, IL). Sequencing grade
modified trypsin was supplied by Promega (Madison, WI).

Equipment

Electro-Eluter model 422 (BioRad) coupled with a power PAC 1000 power
supply (BioRad) was used for three-layer sandwich gel electrophoresis. A Finnigan LCQ
Deca ion trap mass spectrometer (San Jose, CA) coupled with LC Packings Ultimate 47
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quaternary capillary LC system (San Francisco, CA) was used for mass spectrometric
analysis.

Instrument Optimization – Effect of Inlet Capillary Temperature

The purpose of the following procedure is to determine the most optimal inlet
capillary temperature. Vasopressin and neurotensin were dissolved in mobile phase made
of 94.9% water, 5% of acetonitrile and 0.1% of formic acid and used as standard
peptides. Single charged ions of vasopressin and neurotensin are 1085.4 and 1030. 5
respectively, while their double charged ions are 542.7 and 515.7 respectively.
The instrument was set up for the syringe infusion and tuned. The ratio of single to
double charged ions at different temperatures was measured for both peptides using that
tuning file while constantly infusing the standard peptide solution and acquiring data.
Intensity of each ion was averaged over 10 minute time frame. The temperature was
changed in increments. The temperature at which the double charged ions are favored is
chosen for semi-automatic retuning. The new tuning file and the inlet capillary
temperature were used for mass spectrometry analysis.
The effect of the inlet capillary temperature was also examined when a
chromatographic separation was included. For that reason neurotensin was analyzed at 2
temperatures (150 °C and 220 °C) using the tuning files for each temperature,
chromatographic separation utilizing gradient elution (load method of MudPit) and C18
column. Gradient elution was 110 minutes long.
The mobile phase composition was first held at the appropriate mix of solvents C and
D for 15 min (0 to 15 min), and then was switched to solvent A for additional 2 min (15
to 17 min). The gradient was linearly changed from 100% to 50% over 48 min (17 to 65
min) and from 50% to 20% over 20 min (65 to 85 min). The mobile phase composition
was returned to 100% of solvent A in 5 min (85 to 90 min) and held at 100% for the next
20 min (90 to 110 min).
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Cell Culture Growth, Maintenance and Lysis
HeLa cell lines were maintained in α-Minimal Essential Medium (α-MEM)
supplemented with 7% dialysed fetal bovine serum, 2 mM L-glutamine, 100 U/mL
penicillin, and 100 μg/mL streptomycin.
Since the tissue culture media contains Ca2+ and Mg2+ ions and proteins from fetal
calf serum (FBS) that can inhibit trypsin, the plates containing confluent layer of HeLa
cells were washed with sterile PBS then covered with 0.05 % trypsin solution and
incubated for 4 minutes at 37 °C to release them from substratum.
Cells were transferred to 14 mL test tube and centrifuged for 5 minutes at 2000
rpm. The media was removed and the cell pellet was washed with PBS and centrifuged
again. The washing procedure was performed 3 times in total.
The cell lysis was performed in two different buffers. One of the samples was
dissolved in 1 mL of RIPA buffer (10 mM tris-HCl (pH 7.5), 140 mM NaCl, 0.5% (w/v)
sodium deoxycholate, 0.1% (w/v) SDS, 0.025% (w/v) sodium azide, 2 % (v/v) TritonX100). Cells were lysed by passage through a 27 ½ gauge needle. Whole cell lysates were
centrifuged (2000 rpm, 5 min) to remove unlysed cells and cell debris. Supernatants of
multiple lysates were merged together and taken for further analysis.
The other cell lysis sample was dissolved in 1 mL of 10 mM tris buffer (pH 7.5)
with 150 mM NaCl. Cells were lysed by passage through a 27 ½ gauge needle. Whole
cell lysates were centrifuged as described above. Supernatants of multiple lysates were
merged together and taken for further analysis.
Protein concentration was determined by bicinchoninic acid assay (BCA)
according to manufacturer’s instructions.
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Lectin Pull-down

Cell Lysate Preparation

To the HeLa cell lysate calcium chloride and manganese chloride were added to
the final concentration of 1 mM. Also, protease inhibitor as well as SDS to the final
concentration of 0.05 % were added to the volume containing 1 mg of protein,
determined by BCA.

Con A Column Preparation

Three Con A columns were freshly prepared for each sample. Two milliliters of
settled Con A resin were placed in each 5 mL plastic filter tube with the frit at the
bottom. Each resin was washed with 15 mL of the column wash buffer (10 mM Tris, pH
7.5, 150 mM NaCl, 1 mM CaCl2 and 1mM MnCl2). Immediately after preparation the
sample was applied to the column.

The Pull-down Procedure

Depending on the protein concentration, 3-4 mL of the whole cell lysate were
applied to the first Con A column and incubated over night at 4 °C on the rotator (Figure
3.6). The following day the flow through fraction from the first column was applied
directly to the freshly prepared second Con A column. To ensure all the flow through
exited the first column, 1.5 mL of column wash buffer was applied to the first column
and the flow through was caught in the second column until the flow stopped. The
second column is then placed on the rotator and incubated over night at 4 °C.
The first column was washed with 15 mL of column wash buffer. Four milliliters
of commercially obtained Vector Labs elution solution were applied to the first column
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and incubated for 4 hours at room temperature on the rotator. Glycoproteins were eluted
from the column directly into two dialysis cups. To ensure all the Vector Labs elution
solution exited the first column, 1.5 mL of 25 mM ammonium bicarbonate buffer was
applied to the column and eluate was caught until the flow stopped. The eluate, divided in
two dialysis cups, was dialyzed for 24 hours against 9 L of 25 mM ammonium
bicarbonate buffer.

Figure 3.6. The pull-down procedure.

The following day, the procedure was repeated for the second and third column. The
flow through fraction from the second column was applied directly to the freshly
prepared third Con A column. To ensure all the flow through exited the second column,
1.5 mL of column wash buffer was applied to the second column and the flow through
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was caught in the third column until the flow stopped. The third column is then placed
on the rotator and incubated over night at 4 °C.
The second column was washed with 15 mL of the column wash buffer. Four
milliliters of Vector Labs elution solution were applied to the second column and
incubated for 4 hours at room temperature on the rotator. Glycoproteins were eluted
from the column directly into two dialysis cups. To ensure all the Vector Labs elution
solution exited the second column, 1.5 mL of 25 mM ammonium bicarbonate buffer was
applied to the column and eluate was caught until the flow stopped. The eluate, divided in
two dialysis cups, was dialyzed for 24 hours against 9 L of 25 mM ammonium
bicarbonate buffer.
The final day of the sample preparation, glycoproteins from the third Con A
column were eluted. The flow through fraction was stored at -20 °C and the column was
washed with 15 mL of the column wash buffer. Four milliliters of Vector Labs elution
solution were applied to the third column and incubated for 4 hours at room temperature
on the rotator. Glycoproteins were eluted from the column directly into two dialysis
cups. To ensure all the Vector Labs elution solution exited the third column, 1.5 mL of
25 mM ammonium bicarbonate buffer was applied to the column and eluate was caught
until the flow stopped. The eluate, divided in two dialysis cups, was dialyzed for 24 hours
against 9 L of 25 mM ammonium bicarbonate buffer.
The columns for all samples were made of fresh Con A resin to avoid sample
contamination.

Dialysis

Proteins were eluted from the Con A column with 4 mL of Vector Labs elution
solution. Since the capacity of the dialysis cup was only 2 mL, the eluate was placed into
2 dialysis cups with molecular weight cutoff limit of 3.5 kDa. The cups were placed on
the holder and the bottom was submerged in 1.5 L of stirred 25 mM ammonium
bicarbonate pH 8, as shown in the (Figure 3.7). Ammonium bicarbonate solution was
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replaced every 2 hours for four times and after 4 hours the fifth time. The sixth and final
1.5 L of ammonium bicarbonate was left over night.
The following day the membrane on the bottom of the dialysis cups was sealed
with parafilm to prevent leakage and sweating of the regenerated cellulose membrane and
the cups were placed in their 50 mL test tube. The samples were now ready for digestion.

Figure 3.7. A. Dialysis set-up. B. Closer look at the regenerated cellulose membrane.

The Three-layer Sandwich Gel Electrophoresis

A three-layer sandwich gel was prepared in 5 mL plastic filtration tube with the
frit at the bottom. The gel was consisted of an acrylamide sealing layer at the bottom, an
acrylamide concentration layer in the middle and an agarose loading layer on the top.
The tube was sealed with the stopper during the preparation process to prevent
liquid leakage before the polymerization completion.
The gel and the sample were made according to the recipes and procedures
outlined in the publication by Liu et. al. [73]
Briefly, the monomer solution for the sealing layer was loaded to the tube,
covered by 200 μL of a 1-butanol and allowed to polymerize for 30 minutes after which
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the monomer solution for the concentration layer was loaded to the tube, covered by 200
μL of a 1-butanol and also allowed to polymerize for 30 minutes.
The solution of 10 % SDS was added to the sample and incubated at 60°C for 10
minutes. Agarose loading layer, containing the sample, was prepared according to the
recipe, quickly transferred to the tube and allowed to cool at 4°C for 10 min. At the end,
10 μL of 0.5% agarose with 1% Bromphenol Blue was overlaid on the gel to monitor
electrophoresis. Running buffer was prepared according to the Laemmli’s protocol. [76]
The gel was run at 15V for 30min, 5V overnight and at gradually increased voltage to
150V until the dye front was at the interface of the concentration and the sealing layer.

Sample Preparation for Mass Spectrometric Analysis

Digestion of proteins for the dialyzed samples was performed by adding a trypsin
solution directly to the dialysis cup and incubating for 18 hours at 37 °C water bath. The
amount of added trypsin varied depending on the elution. To the eluate from the first
column 10 µg of trypsin was added, while 5 µg each were added to the second and third
eluate. After digestion, the peptides were transferred to 1.5 ml test tube and dried using
vacuum centrifuge.
Digestion of proteins obtained by TSGE method started with excising the
concentration layer of the gel and cutting it to the smallest pieces. These pieces were
placed in the 1.5 mL test tube and covered with 50 mM ammonium bicarbonate buffer.
After 10 minutes incubation at room temperature the buffer was removed and the pieces
were covered with the buffer consisted of equal amounts of acetonitrile and 50 mM
ammonium bicarbonate. After 10 minutes incubation at room temperature that buffer
was replaced with the pure acetonitrile and incubated for additional 10 minutes at room
temperature yielding dried gel pieces. After removal of acetonitrile the pieces were
covered with the solution of trypsin in 25 mM ammonium bicarbonate and incubated at 4
°C for 40 minutes. During that time the gel pieces swelled by absorbing the trypsin
solution. The excess solution was removed and enough of 25 mM of ammonium
bicarbonate was added to cover the gel pieces. After this, the gel pieces, closed in the 1.5
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mL test tube were incubated at 37 °C overnight. The following day peptides were
recovered by transferring the buffer solution into the new 1.5 mL test tube. Remaining
gel pieces were further extracted with 100%acetonitrile and transferred to the buffer tube.
The resulting peptide solution was dried using vacuum centrifuge.
Dried peptides obtained from any of the two procedures described above were
reconstituted in 20 µL of a mobile phase containing 94.9 % optima water, 5 % of optima
acetonitrile and 0.1 % formic acid and analyzed by Finnigan LCQ Deca ion trap mass
spectrometer utilizing MuDPIT method.

Mass Spectrometry Analysis

Finnigan LCQ Deca ion trap mass spectrometer coupled with a LC Packings
Ultimate quaternary capillary LC system was used for the mass spectrometry analysis of
peptides.
Twenty microliters of digested glycoproteins obtained from the whole HeLa cell
lysate were injected onto a laboratory fabricated fused silica capillary strong cation
exchange (Partisil SCX) column (350 μm I.D. x 5 cm, 10 μm particles). This column
was directly connected to a laboratory fabricated fused silica capillary C18 column (350
μm I.D. x 15 cm, Microsphere 3.5 μm particles). Columns were packed using a stainless
steel packing cell. LC Packings Ultimate quaternary capillary LC system with a 20 µL
injection loop was used for the sample and mobile phase delivery at 4 µL/min.
Mobile phase A was comprised of 94.9% optima grade water, 5% optima grade
acetonitrile and 0.1% formic acid. Mobile phase B was comprised of 94.9% optima
grade acetonitrile, 5% optima grade water and 0.1% formic acid. Mobile phase C was
comprised of 300 mM ammonium acetate in optima grade water and mobile phase D was
the same composition as mobile phase A.
Two-dimensional LC separation was performed with 12 isocratic salt elution
where the following salt concentrations of 0 mM, 5 mM, 10 mM, 15 mM, 20 mM, 30
mM, 40 mM, 50 mM, 100 mM, 150 mM 225 mM and 300 mM were obtained by

53

appropriately mixing mobile phase C with mobile phase D. The 13th salt step was
obtained by direct injection of 20 µL of 3 M ammonium acetate.
Each salt elution was followed by a 110 min C18 reversed-phase gradient elution.
The mobile phase composition was first held at the appropriate mix of solvents C and D
for 15 min (0 to 15 min), then was switched to solvent A for additional 2 min (15 to 17
min). The gradient was linearly changed from 100% to 50% over 48 min (17 to 65 min)
and from 50% to 20% over 20 min (65 to 85 min). Mobile phase composition was
returned to 100% of solvent A in 5 min (85 to 90 min) and held at 100% for the next 20
min (90 to 110 min).
The voltage applied to electrospray source was 3.5 kV and 20 units of sheath gas
flow. I Inlet capillary was held at 35.0 V and 150 °C. Other parameters were as follows:
tube lens offset at -15.0 V, multipole 1 offset at -7.5 V, lens voltage at -50.0 V, multipole
2 offset at -13.0 V, multipole RF amplitude peak-peak at 400 V, entrance lens at -50.0 V
and trap DC offset at -10.0 V.
Mass spectrometer was operated in a data-dependent mode. The full scan from
m/z 200 to 2000 was acquired first. The most intense precursor ion was selected from the
previous full MS scan and submitted to collisional induced dissociation (CID) with an
activation Q of 0.250, activation time of 45 ms, and 35% normalized collision energy
(NCE). This was followed by a MS/MS scan between m/z 200 and 2000 of the most
intense ion of the previous full MS scan. The same procedure was performed for three
most intense ions that were excluded from further tandem experiments for one minutes.
Each analytical full scan was constructed as an average of 3 full scans, while each
analytical MS/MS scan was constructed as an average of 5 MS/MS scans.
Maximum ion trap injection time of 300 ms was used for the full scans and 500
ms was used for MS/MS scans. Automatic gain control (AGC) target for the full scan
was set to 2 x 107 and for MS/MS to 5 x 107.

54

Protein Data Analysis

All 13 RAW files of a MuDPIT run were uploaded to the MASCOT daemon
software, combined as one file and searched against SwissProt, human taxonomy.
Parameters were set as followed: cleavage enzyme was trypsin with three missed
cleavage allowed. Peptide tolerance and the MS/MS tolerance were set to 1.0 Da.
Oxidized methionine was chosen as a variable modification.
MudPIT scoring was used and the requirement for positive protein identification
was bold red. This requires the protein hit to include at least one bold red peptide match
indicating that the peptide is the highest scoring match to the MS/MS spectra.
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Results and Discussion

Instrument Optimization – Effect of Inlet Capillary Temperature

C-terminus of peptides digested with trypsin have arginines (R) or lysines (K),
two most basic or hydrophilic amino acids. Their carboxylic groups are neutral (COOH)
in the solution due to free formic acid in the mobile phase. The first proton will reside at
the residue of R or K making NH3+ of initial NH2 because that is the most nucleophilic
group. This proton will not change its place in the process of excitation and
fragmentation. This would lead to loss of information about the sequence. However, the
second proton can be anywhere along the backbone and reside at any carbonyl group.
Upon excitation, the peptide can fragment anywhere along the peptide bond yielding two
charged fragments permitting detection of both. In a population of a certain peptide there
will be a statistical distribution of proton locations that will give different fragments
allowing us to determine the peptide sequence. For all these reasons it is imperative to
have at least 2+ precursor ions for the MS/MS analysis.
Increased temperature of the inlet capillary increases the statistical probability of
singly charged precursor ions because the high kinetic energy increases the breakage of
hydrogen bonded water that can take the proton along with it. Therefore, it is necessary
to determine the optimal inlet capillary temperature.
Two commercially available peptides, neurotensin and vasopressin, were separately
infused into mass spectrometer. Data were acquired continuously but intensity of ions
was averaged over 10 minute time frame when the temperature of the capillary was
equilibrated. The temperature was changed incrementally and plotted against the average
ratio of intensity of single-to-double charged ions for a given temperature (Figure 3.8).
The higher abundance of double charged ions was confirmed for the temperature of 150
°C.
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Figure 3.8. Inlet capillary temperature optimization with infusion for neurotensin and
vasopressin.

The ratio of single and double charged ions was also examined with chromatographic
separation utilizing neurotensin as standard peptide. Results show higher abundance of
double charged ions at 150 °C (Figure 3.9) and that temperature was chosen as optimal
for further work.

Figure 3.9. Inlet capillary temperature optimization with chromatographic separation for
neurotensin.
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Cell Disruption method and Protein Denaturation

The choice of the cell lysis and protein denaturation method depends on
compatibility with downstream analysis. For the analysis of glycoproteins, cell lysate is
applied to the Con A column, therefore, the buffer containing the cell lysate has to be
chosen so that Con A retains its binding activity. Con A is found to tolerate up to 0.05%
of SDS, 1% of Triton-X and NP-40. On the other hand, RIPA buffer is one of the most
efficient buffers used for the cell lysis. Hence, the stability of the Con A column was
tested for the cell lysate in RIPA buffer.

Figure 3.10. Elution profile of mannose-BSA (1 mg/mL) in RIPA buffer.

Results, shown in the Figure 3.10, represent the protein concentration in 250 µL
fractions calculated by measuring the absorbance at 280 nm. Fractions were caught from
the gravity flow Con A column. Mannose-BSA was used as a standard protein to bind to
the Con A and was eluted with the Vector Labs elution solution.
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The highest protein concentrations were detected in the flow through fractions
confirming that Con A lost its binding activity thus eliminating RIPA buffer as a choice
for the cell lysis.
Mechanical shearing is alternative approach that disrupts the membrane of the
cells but detergents are still required to release membrane- or cytoskeleton- bound
proteins. Also, proteins retain their native structure preventing efficient digestion
downstream.
Following the elution, digestion is the next step in sample preparation that needs
to be considered when choosing cell lysis and denaturation method. Trypsin is the most
widely used protease that specifically cleaves proteins at carboxyl terminus of arginine or
lysine unless there is adjacent proline. Peptide fragments with one missed cleavage are
common due to blocked or slowed digestion, for example in the case of multiple adjacent
cleavage sites or if an acidic residue is on either side of the cleavage site. Also when the
protein is in its natural folded state not all arginines and lysines are accessible for
digestion. Therefore, detergents are used to unfold and denature the proteins allowing for
more efficient digestion. On the other hand, trypsin is also a protein, and therefore,
sensitive to the presence of detergents. Trypsin retains most of its activity in 0.1% (w/v)
SDS solution.
All things considered, heating the cell lysate containing low amount of SDS at 95
°C for 5 minutes was reported as viable alternative. [77] The increase in temperature
increases the kinetic energy of the protein, which disrupts the weak bonds and allows for
equally probable multiple microstates of the protein to exist. Consequently, entropy
raises and protein’s random structure is favored, which facilitates digestions due to more
accessible cleavage sites.
To explore this approach, the new batch of HeLa cells was lysed in tris buffer and
0.05% SDS was added post lysis obtaining aliquots for 2 samples. Samples were treated
exactly the same except one of them was heated 95 °C for 5 minutes and cooled to the
room temperature before applying on to Con A column. The cooling to the room
temperature was necessary because the sample was applied to the Con A, which is also a
protein and, therefore, prone to denaturation at high temperatures.
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Figure 3.11. The effect of cell lysate heating to the qualitative identification of the
proteins. Purple circle: no heat involved. Red circle: heated sample.

Results, shown in the Figure 3.11, suggest that heating the sample does not
increase the number of identified proteins. As the increase in temperature results in
protein unfolding, cooling process allows for random refolding of denatured proteins
decreasing the number of accessible cleavage sites. This results in long peptides with
multiple missed cleavages that fall outside of the analytical window of the mass
spectrometry method and thus lower the number of identified proteins. However, due to
randomness some cleavage sites remain accessible allowing for additional 66 proteins
from the heated sample to be identified. The heating approach was abandoned since it
yielded overall less proteins.
In conclusion, the cells were lysed in 10 mM tris buffer, pH 7.5, 0.15 M NaCl and
protease inhibitor. To prevent foam formation 0.05% SDS was added after lysis as well
as 1 mM CaCl2 and 1 mM MnCl2 required for subsequent binding to Con A.

Elution Buffer Evaluation
Con A binds glycoproteins containing α-mannose, α-glucose and N-glycans on
their surface when the whole cell lysate at the neutral pH containing calcium and
manganese is applied to ConA column. Applying binding inhibitors, such as methyl-αD-mannopyranoside, will release glycoproteins from binding pocket of Con A. The
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release is further enhanced by removal of metal ions and decrease of the pH when Con A
reversibly loses its binding ability. However, low pH is not suitable for downstream
protein digestion due to reversible inactivation of trypsin. Therefore, the solution of
binding inhibitor at neutral pH is preferred because it eliminates the need for subsequent
buffer exchange.
Achieving a complete elution with the in-house prepared binding inhibitor
solution can be difficult while commercially available solutions promise a complete
elution but are a proprietary blend of unknown composition thus requiring a subsequent
buffer exchange. For that reason we tested two elution solutions. The first was in-house
made tris buffer without added metal ions at pH 7.5 containing 0.2 M methyl-α-Dmannopyranoside. The second elution solution (Vector Labs elution solution, ES 1100)
with pH 3.0 and undisclosed composition was purchased.
Two samples, of the same protein concentration and otherwise treated the same,
were eluted from the Con A column using either tris buffer at pH 7.5 or commercially
obtained solution at pH 3.0.

Figure 3.12. The effect of the composition of elution solution on the qualitative
identification of proteins. Green circle: Vector Labs elution solution. Blue circle: 10
mM tris pH 7.5 with 0.2 M α-methyl-mannoside and 0.2 M α-methyl-glucoside.
Results, shown in the Figure 3.12, prove more efficient elution utilizing
commercially obtained solution. However, not all proteins identified utilizing tris buffer
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are also identified using the Vector Labs elution solution probably due to pH sensitivity
of those proteins. Nevertheless, the Vector Labs elution solution was chosen for further
sample processing.

Development of glycoprotein purification method

The purification method set up is outlined in the Figure 14. In brief, the whole
cell lysate was applied to the first Con A column. Non-retained protein fraction (first
flow-through) was passed through a second Con A column and then the second nonretained protein fraction (second flow-through) was passed through the third Con A
column yielding 3 sequential pull-downs.
Glycoprotein eluting solution was applied to each column to elute the retained
protein fraction. Glycoproteins were eluted from the column directly into two dialysis
cups and dialysed against 25 mM ammonium bicarbonate buffer.
After dialysis the bottom of the dialysis cup was sealed and proteins were
digested directly in the cup by adding a trypsin solution. After digestion, peptides were
dried using vacuum centrifuge and reconstituted in a mobile phase appropriate for the
mass spectrometry analysis utilizing MuDPIT method.
To achieve the best yield of this method development the steps of this protocol
were individually assessed and optimized. For that purpose HeLa whole cell lysate was
utilized as benchmark.

Comparison of three layer sandwich gel and dialysis for purification of glycoproteins

Glycoproteins are eluted in commercially obtained, very viscous Vector Labs
elution solution incompatible with the downstream tryptic digestion due to low pH of 3.0.
Adjusting the pH of the blank Vector Labs elution solution (no proteins) with ammonium
hydroxide invoked precipitation. For that reason, the solution containing eluted proteins
had to be exchanged with 25 mM ammonium bicarbonate pH 8 that is preferred solution
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for the tryptic digestion. Thus two methods were evaluated: three layer sandwich gel and
dialysis.

Three layer sandwich gel electrophoresis

As described in introductory part of this chapter, three layer sandwich gel
electrophoresis (TSGE) proved to be superior clean-up method for the protein solutions at
near neutral pH, containing high concentrations of salts and detergents. [73] However,
protein solution obtained after elution from the Con A column contains high saccharide
concentration at pH 3.0 in proprietary solution due to elution with the Vector Labs
elution solution. Therefore, TSGE has to be evaluated for this settings as well.
To that end, BSA coupled with glucose (g-BSA) was commercially obtained and
used as a standard. The standard sample was prepared by dissolving 400 µg (10 µL
stock) of g-BSA in 390 µL of Vector Labs elution solution. This standard sample was
loaded and TSGE was run. In spite of running the gel for 28 hours the bromophenol
blue, considered as zero molecular weight marker, never reached the concentration layer
but was observed in the middle of the agarose gel. Nevertheless, the concentration layer
was excised and treated as if proteins were prepared for the mass spectrometry analysis.
However, the mass spectrometry analysis showed no significant protein hits raising the
question if the problem was Vector Labs elution solution or the protein glycosylation.
These two questions were obvious because the Vector Labs elution solution
already showed precipitation when attempting to adjust the pH from 3.0 to 7.5. On the
other hand, saccharides are hydrophilic but uncharged compounds. Therefore,
glycosylated proteins extensively decorated with saccharides may not be able to see the
electric field due to the shielding effect of saccharides on the protein surface. To give an
answer to this question two experiments were performed.
The first experiment involved comparison of TSGE of glycosylated protein
standards versus non-glycosylated protein standards, both diluted with Vector Labs
elution solution to the same concentration yielding 2 samples. Both samples, g-BSA and
non-glycosylated BSA, of the same concentrations were prepared from their respective
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standard stock solutions by dilution in Vector Labs elution solution and TSGE was run.
Both samples yielded same results with the bromophenol blue in the middle of agarose
gel and no significant protein hits by mass spectrometry.
To exclude protein glycosylation as a possible impediment for TSGE
methodology, the next set of two samples were prepared exactly the same as described in
the paragraph above except the protein stock solutions were dissolved in solution
containing 10 mM tris buffer, pH 7.5, 0.15 M NaCl and 0.2 M α-methyl-mannoside as a
binding inhibitor. In both samples the bromophenol blue was found at the bottom of the
concentration layer after the overnight run. The concentration layer was excised and
samples were prepared for mass spectrometry analysis. BSA was identified in both
samples confirming that protein glycosylation does not pose an obstacle for TSGE
methodology.
The next experiment addressed the question of the compatibility of Vector Labs
elution solution with TSGE and for that reason no proteins were included in this
experiment. To that end four samples with the decreasing concentrations of the
commercially obtained eluting buffer (100%, 75%, 50%, 25% and 0% in tris buffer) were
prepared according to the recipe for TSGE sample preparation. Additionally, two
samples containing decreasing concentrations of binding inhibitor (α-methyl-mannoside)
were also prepared in tris buffer, pH 7.5, with 0.15 M NaCl to examine effects of the
monosaccharide on the TSGE gel. Gels were run over night as outlined in the protocol
for TSGE. [73] Results are shown in the Figure 21.
Bromophenol blue dye has a molecular weight of 670 g/mol and is negatively
charged at neutral pH thus migrating at the same direction as proteins in the electric field.
For that reason, besides using the color of bromophenol blue to visualize the progress of
the experiment, this dye can be used as a “zero molecular weight” marker, which was
exactly its purpose in this experiment.
It is obvious from the Figure 2.13 that the movement of bromophenol blue depends
on the concentration of Vector Labs elution solution but not on the concentration of the
binding inhibitor; the higher the concentration of the Vector Labs elution solution the less
movement of the dye. Dye moved 22.2% further down the agarose gel when the
concentration was decreased by 25%. However, this is not a linear dependence because
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the dye moved 77.8% further down the agarose gel when the concentration was decreased
by 50% of its initial concentration. It is evident that diluting the Vector Labs elution
solution to 25% of its initial concentration leads to bromophenol blue reaching the
concentration layer. But that would not be feasible when eluting the glycoproteins with 4
mL of Vector Labs elution solution because the dilution would yield 16 mL of much
diluted sample known to suffer of high protein loss in subsequent sample treatment.
Considering gels containing the binding inhibitor in tris buffer, the concentration of
the binding inhibitor has no effect on the bromophenol blue movement in the electric
field. Therefore, some other component of proprietary Vector Labs elution solution is
causing the problem.
As previously stated, the pH adjustment of the Vector Labs elution solution led to
precipitation. Out of curiosity if the precipitate formed within the gel as well, gels were
stored at 4 °C for 2 days to allow the dye to diffuse and then visualize the site of the dye
build-up (Figure 3.14).

Figure 3.13. Sandwich gel with dye in different concentrations of ES-1100 or Tris + αmethyl- mannoside elution solution.
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Figure 3.14. Sandwich gel with dye in different concentrations of ES-1100 or Tris + αmethyl-mannoside elution solution after 2 days in 4°C.

Even after the dye diffused throughout the gel the white precipitate was obvious
in two gels with the highest concentration of Vector Labs elution solution but less so in
the third and fourth gel where the concentrations were 50% and 25% respectively (Figure
3.14).
These experiments led to conclusion that TSGE method is not suitable for use
with Vector Labs elution solution (ES-1100) due to precipitation within the agarose gel.
For that reason another method had to be considered and dialysis was the next logical
option.

Dialysis

Dialysis is one of the most widely used methods for sample purification and
buffer exchange by concentration gradient driven separation based on the diffusion
through a semipermeable membrane. However, one of the draw-backs of dialysis is loss
of proteins because they tend to stick to the membrane as well as the wall of the plastic
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cup. For that reason digestion was conducted within the cup allowing for parts of the
stuck proteins to be digested. Even though digestion of those proteins would not be
complete, available peptides would contribute to their identification consequently
increasing the number of the identified proteins.
In practice, 3 mg of whole cell lysate was applied to the Con A column and
incubated overnight at 4 °C. Retained proteins were eluted with 4 mL of Vector Labs
elution solution into two dialysis cups and dialyzed against 25 mM ammonium
bicarbonate for 24 hours. The following day trypsin was added directly to the dialysis
cups and proteins were digested overnight. After the sample was dried and reconstituted
in the mobile phase, mass spectrometry analysis was performed utilizing MuDPIT
separation.
As a result 295 proteins were identified with false discovery rate of 17.03% and
highest score of 964 making this procedure a method of choice for buffer exchange.

Sequential Pull-down Method

Binding of glycoproteins to a lectin depends on how well does the exposed glycan
fit into the binding pocket of the lectin. Glycan that fits better will replace the weakly
bound ones due to increase of the bond strength and decrease of the free energy of the
bound state. Therefore, weakly bound proteins can be replaced by proteins that bind
more tightly.
To analyze glycoproteins with the lower binding affinity sequential pull-down
method was evaluated. In this method the sample was applied to the first Con A column
and the non-retained protein fraction (first flow-through) was passed through a second
Con A column and then the second non-retained protein fraction (second flow-through)
was passed through the third Con A column (3 sequential pull-downs). Employing the
sequential pull-down glycoproteins that bind with the highest affinity are retained in the
first pull-down allowing for the weaker bound ones to be retained in the next pull-down
and even weaker in the third one.
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To that end, 3 mg of the whole cell lysate were applied to the Con A column and
processed as described. Results, shown in the Figure 3.15, prove that flow through after
the first and second pull-down still contain glycosylated proteins. Even though vendor
claims 1 mL of settled Con A resin can capture 4 mg of ovalbumin, these results prove
that 1.5 mL of settled Con A resin cannot capture all glycoproteins in 3 mg of the whole
cell lysate. After the second pull-down, 39 additional proteins were identified and 32
after the third pull-down. In total, 366 proteins were detected, which is 19.4% more than
with only the first pull-down.
As mentioned before, the whole cell lysate contains 0.05% SDS. Even though
Con A is not denatured by such low concentration of SDS, there is still a possibility that a
certain percentage of Con A molecules will lose their activity. Besides the binding
strength explained above, this activity loss can be another reason for identifying unique
proteins in the second and third pull-down. Moreover, proteins can bind in non-specific
fashion in any of the three columns thus increasing the number of unique proteins
identified in any of the three pull-downs.

Figure 3.15. Sequential pull-down. Purple circle: first pull-down. Orange circle: second
pull-down. Yellow circle: third pull-down.

Reproducibility of this approach was evaluated with the analysis of three samples
of the same amount of protein (1.4 mg). Samples were all prepared from the same whole
cell lysate and treated the same. Results of the total number of identified proteins in each
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samples are presented in the table 3.2 below along with the highest protein score and
false discovery rate (FDR).

Table 3.2. Results of the triplicate sample analysis.
sample

# protein

FDR

highest score

1

159

16.35%

955

2

193

12.16%

1091

3

226

11.51%

1815

On average 193 proteins were identified with the standard deviation of 34.
However, utilization of mass spectrometry and bioinformatics tools provide
deeper understanding of the obtained results, therefore, further validation of this method
of isolation of glycoproteins can increase the confidence in database searching results. A
better understanding of results starts with understanding of types of acquired peptides and
their fragmentation products. Some peptides have N-glycosylation consensus sequence
as a part of the amino acid sequence but some do not. Peptides with the consensus
sequence may carry a glycan attached to it but not all of them do. The most abundant
peptides that reach ion trap undergo fragmentation. The peptide fragmentation can be
invoked anywhere along the peptide backbone breaking the peptide bonds. The fragment
that carries the charge is the detected ion that can be identified by the search against the
protein database for the particular organism. However, glycans attached to peptides can
produce ions of larger mass or even sterically block trypsin to access the cleavage sites
due to their elaborate structure and prevent the digestion of that site. [78] For those
reasons many peptides will not be identified because their masses do not match the
masses of the peptides in the database. If the glycan is very complex and introduces a
much larger increase in mass or the peptide has multiple missed cleavages, the mass of
that peptide may not fall within the detection range of the mass spectrometer used
preventing the ion to even be detected. However, if the mass of the glycan is known and
not too large, the mass of the expected ion can be calculated and the perceived peptide
can be searched manually. But that does not mean that peptides with the consensus
sequence cannot be identified automatically. About two thirds of proteins that contain
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the consensus sequence are actually glycosylated. Remainders are identified as potential
N-glycan sites. Therefore, it is possible to identify peptides with the consensus sequence
but experimental proof of N-glycan is required. For all these reasons, some peptides with
the consensus sequence will be detected but some will not. One example of such
occurrence is endoplasmin that is used here as an example of the identified proteins and
thereof analysis.
Endoplasmin precursor has a nominal mass of 92411, 803 amino acids sequence
and calculated pI value of 4.76. In UniProtKB/Swiss-Prot database it is listed under the
code P14625 (ENPL_HUMAN) and under the name “endoplasmin”. This molecular
chaperone is found in endoplasmatic reticulum and helps transport and process secreted
proteins. It also serves in ER-associated degradation (ERAD) of terminally misfolded or
unassembled proteins. [79]
Utilizing this method, endoplasmin was identified with the score of 368 with
sequence coverage of 43%. The protein sequence is shown below with the identified
peptides in red color and the ones that were not identified in black color.

Considering consensus sequence for N-glycosylation there are 8 possible Nglycosylations sites (underlined) but only two, at Asn-217 and Asn-445, have been
reported (underlined and bold italic). [80]
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Even more details can be obtained on the peptide level. For example, let’s
consider the ion 638.75 m/z from the list of ions assigned to endoplasmin (Figure 3.16).
Since 638.75 m/z ion is doubly charged, it was identified with the mass of 1275.48 m/z
for the singly charged ion. Singly charged ion was matched with the neutral peptide with
calculated monoisotopic mass of 1274.64 m/z. The fragmentation pattern of 638.75 m/z
ion was matched with the sequence ELISNASDALDK. Out of 129 predicted ions shown
in the table 3.3, 29 were identified (bold) by analysis of 36 most intense peaks shown in
the mass spectrum below.

Figure 3.16. Mass spectrum: A. Full mass spectrum (MS), B. Mass spectrum of
fragmented ion (MS/MS)
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Table 3.3. List of expected fragment ions of the ion 638.75 m/z. Detected in bold.

Considering chromatograms (Figure 3.17), if only total ion chromatogram at
38.15 minutes no discernable peaks are observed. However, if the chromatogram of only
a single ion is extracted the peak is obvious.

Figure 3.17. Chromatogram: A. Total ion chromatogram, B. Single ion chromatogram
for the ion 638.75 m/z.
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In light of the fast development of bioinformatics tools, one could argue that
identified glycoproteins could be extracted from the list of identified proteins from the
whole cell lysate acquiring only proteins with appropriate consensus sequence and hence
significantly decrease the sample handling time. However, there are two obstacles to that
simplified approach. First, a protein can have multiple consensus sequences but glycans
will not be attached to all of them. Hence the glycosylation has to be confirmed and the
lectin binding is a viable conformation. The second obstacle is the sample complexity.
Glycosylation of the human proteome is at the level of 5%. Since only the most abundant
proteins are identified, glycoproteins would compete for identification with a large
number of other proteins in the mixture and thus would very likely not to be identified.
Therefore, the reduction in sample complexity utilizing the lectin pull-down method
provides a substantial advance in protein identification.

Conclusion

Up to date, there is no one method capable of profiling all proteins present in the
whole cell lysate. Therefore, sample separation and purification methods are developed
as an answer to the particular question about the proteome. Sample preparation for mass
spectrometry analysis is a critical step in the proteomics workflow because the quality
and reproducibility of sample extraction and preparation significantly impacts the
separation and identification capabilities of mass spectrometers. The additional obstacle
is to extract only glycosylated proteins for which there is no one standard method.
The method discussed in this chapter was developed in an effort to identify as
many as possible N-glycosylated proteins. This is achieved by application of the whole
cell lysate to agarose bound Concanavalin A (Con A) beads to efficiently pull down
glycoproteins, dialyze and analyze them using MuDPIT. This method was further
enhanced by passing the non-retained protein fraction (first flow-through) through a
second Con A column and then passing the second non-retained protein fraction (second
flow-through) through the third Con A column (3 sequential pull-downs) yielding 366 N73

glycosylated proteins. Utilizing three sequential pull-downs rather than just one, the
number of identified proteins was increased by 19.4%.
Considering the tendency of proteins to stick to the plastic surfaces, this method
was crafted with minimal protein loss in mind. That was achieved by minimizing the
number of steps in the procedure as well as the equipment. Although the use of more
elaborate separation protocols could increase the depth of protein coverage, there will
always be peptides that are out of the analytical window and will not be identified.

Copyright@Sanja Trajkovic 2014
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CHAPTER 4
GLYCOPROTEOMES OF TACHYZOITES AND TISSUE CYSTS
AND THEIR DIFFERENCIES

Toxoplasma gondii

Toxoplasma gondii, as a member of Apicomplexa phylum, is obligate intracellular
protozoan parasite that causes the disease called toxoplasmosis. Even though humans are
accidental hosts, some estimates suggest that over 30 % of human population is infected.
Infected humans could have parasite colonies anywhere in brain or muscle tissue.
Therefore, human symptoms of toxoplasmosis may depend on parasite’s final location
explaining, for example, the newly found link between schizophrenia and toxoplasmosis.
[81]
Recent studies show that a Toxoplasma gondii found in the brain of mammals
encodes the enzyme for producing dopamine and as consequence production and release
of significantly higher than normal amount of dopamine in infected brain cells. These
findings may change the way dopamine-related neurological disorders as schizophrenia,
attention deficit hyperactivity disorder and Parkinson's disease are treated. [81]
Most infected people are healthy and do not exhibit any symptoms or develop
sore lymph nodes, muscle pains and other minor flu-like symptoms that last for only
several weeks. However, for those who are immune-suppressed, and particularly for
fetus, there are significant health risks that can occasionally be fatal. [81]
Life cycle of Toxoplasma gondii starts with the sexual cycle in its feline definitive
hosts. The cat sheds parasites in the form of oocysts that take 1 to 5 days to sporulate and
become infective. Asexual cycle starts once the intermediate hosts such as birds, rodents,
humans, etc. ingest the material contaminated with oocysts that shortly after transform
into rapidly growing tachyzoites. Once tachyzoites are localized in brain or muscle tissue
they develop into tissue cysts containing bradyzoites. [82]
Bradyzoites and tachyzoites are two interconvertable stages of Toxoplasma gondii
in intermediate hosts. Transmissible bradyzoites are growing slowly making a dormant,
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encysted form. Upon ingestion the cysts’ wall is digested releasing bradyzoites. Being
resistant to gastric proteases, they invade the small intestine where they convert into
rapidly growing, infectious tachyzoites. This form replicates inside a parasitophorous
vacuole (PV), egress, and then infects neighboring cells. Host’s immune system
eliminates most of parasites but enough of them survive and convert back into
bradyzoites and wait until a member of a feline family ingests the intermediate host to
finish their life cycle. [82]
Toxoplasmosis can be treated with combinations of antibiotics as pyrimethamine,
which interfere with RNA and DNA synthesis, with either trisulfapyrimidines or
sulfadiazine that stops folic acid production in parasite but Toxoplasma gondii cannot be
eliminated completely. Parasites can remain within tissue cells in a less active stage
(cyst) in locations difficult for medication to get to.
All this calls for better understanding of Toxoplasma gondii that will point toward
possible cure. The whole proteome of Toxoplasma gondii is yet to be annotated and this
dissertation represents the effort put toward developing a method to study the
glycoproteome of intracellular organisms and consequently increase the knowledge base
of Toxoplasma gondii.

Structure of Toxoplasma gondii

Toxoplasma gondii is a part of Apicomplexa phylum named after distinct apical
complex structure involved in penetrating a host's cell.
Toxoplasma gondii goes through three infectious stages: tachyzoites (rapidly
multiplying), bradyzoites (slow growing) and sporozoites. [83] This dissertation focuses
on tachyzoites and tissue cysts containing bradyzoites.
Tachyzoites and bradyzoites have a similar structure. They are both crescent
shaped, 2 to 6 µm long with pointed front end and rounded back end. They consist of
triple membrane system called pellicle and subpellicular microtubules, apical rings, polar
rings, conoid, rhoptries, micronemes, micropore, endoplasmic reticulum, Golgi complex,
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ribosomes, rough and smooth endoplasmic reticulum, micropore, mitochondrion,
nucleus, dense granules, amylopectin granules and apicoplast. [83]
However, there are some differences as the appearance, position and number of
some organelles. The structure of rhoptries of tachyzoites look like labyrinth while
bradyzoites have uniformly dense rhoptries with some of them folded back on
themselves. Also the nucleus in bradyzoites is positioned toward the front end while
more centrally located in tachyzoites. Higher numbers of micronemes and dense
granules are reported in tachyzoites, while the higher number of amylopectin granules is
observed in bradyzoites. Also, bradyzoites are less prone to proteolytic digestion than are
tachyzoites. [83]
While tachyzoites grow in groups called clones, bradyzoites grow within tissue
cysts. The wall of the tissue cyst is about 0.5 µm thick and elastic and composed of the
host cell and parasite materials. Tissue cysts vary in size depending on the cyst age, from
5 µm for young cysts containing as few as two bradyzoites to 70 µm for the older cysts
that can contain several hundred bradyzoites. [83] .

Glycoproteome of Toxoplasma gondii

Unlike Toxoplasma gondii, majority of members of Apicomplexa phylum cannot
form the tissue cysts. Those members are proved to lack enzymes required for the
Asparagine Linked Glycan (ALG) pathway. However, the analysis of the genome of
Toxoplasma gondii proves the ability of the parasite for N-linked glycosylation
suggesting that N-linked glycosylation may play a key role in the establishment and
maintenance of the tissue cyst. [84]
Glycosylation of tachyzoites of Toxoplasma gondii proteins has been a
controversial issue and demonstrated only recently using lectin pull-down methods and
mass spectrometry that showed the great diversity of glycoproteins in Toxoplasma gondii.
[66, 77, 85, 86] However, the mechanism of transformation of tachyzoites to bradyzoites
and the tissue cyst formation is yet unknown. Also, little is known about the
glycoproteome of tissue cysts except their affinity to react with Dolichos biflorus
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agglutinin (DBA) (Figure 4.1) and succinyl Wheat Germ Agglutinin (SWGA) lectins.
[66] Combining DBA and Con A staining (Figure 4.2) demonstrates the presence of αlinked mannose on the bradyzoites but not the cyst wall.
The evidence suggests that glycosylation could be essential for cyst formation and
maintenance which is characteristic of chronic stage of disease. Therefore, further
studies are required to better understand the interaction between Toxoplasma gondii and
its host in order to develop new preventative and therapeutic strategies.

Figure 4.1. Staining of the tissue cyst. DAPI: Hoechst staining binds to DNA and each
blue spot is an individual parasite. DBA: Dolichos biflorus agglutinin lectin binds to αlinked N-acetylgalactosamines, which are abundantly present on the cyst wall. DIC: dif

Figure 4.2. Staining of the tissue cyst. DBA, stained in green, highlights the cyst wall.
Concanavalin A (Con A), stained in red, recognizes α-linked mannose.
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Experimental

Materials

Trypsin-EDTA (phenol red, 0.05 %) was obtained from Life Technologies (Grand
Island, NY). Protease inhibitor cOmplete was purchased from Roche Diagnostics
(Indianapolis, IN).
Slide-A-Lyzer MINI Dialysis Device, 3.5K MWCO, 2mL and bicinchoninic acid
assay (BCA) were purchased from Thermo Scientific (Rockford, IL). Agarose bound
Concanavalin A (Con A) resin and glycoprotein eluting solution for mannose- and
glucose-binding lectins were purchased from Vector Laboratories (Burlingame, CA).
Ammonium bicarbonate, ammonium citrate, formic acid, methanol, Optima grade
acetonitrile, Optima grade water, calcium chloride dehydrate and manganese chloride
tetrahydrate were purchased from Fisher Scientific (Chicago, IL). Sequencing grade
modified trypsin was supplied by Promega (Madison, WI).

Equipment

A Finnigan LCQ Deca ion trap mass spectrometer (San Jose, CA) coupled with LC
Packings Ultimate 47 quaternary capillary LC system (San Francisco, CA) was used for
mass spectrometric analysis. Thermo French Pressure Cell Press (Rockford, IL) was
utilized for cell lysis.

Cell Culture Growth and Maintenance

Tachyzoites ME49 were grown in the Vero cell line. Vero cells were maintained
in α-Minimal Essential Medium (α-MEM) supplemented with 7% heat-inactivated fetal
bovine serum, 2 mM L-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin.
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Plates with confluent Vero monolayers were infected with 1 x 106 parasites and incubated
at 37 °C until the majority of the Vero cells lysed out. The content of the plates was
transferred to the 14 mL test tube and centrifuged at 2000 rpm for 10 minutes. Parasites
and parasites containing cells were resuspended in 1 mL PBS and selectively lysed by
passage through a 27 gauge needle. After centrifugation the obtained parasite pellet was
washed three times by sequential centrifugation and resuspension in 10 mL sterile PBS.
The final pellet was obtained after centrifugation at 2000 rpm for 10 minutes. Pellets
from multiple plates were merged together and resuspended in 10 mM tris (pH 7.5) with
150 mM NaCl and protease inhibitor. French press at a pressure of 10,000 psi at medium
setting was utilized for parasite lysis.
The purified brain cysts were obtained from Dr Sinai’s laboratory. They were
harvested from CBA/J mice around 3-4 weeks post infection and purified by percoll
gradient purification. Purified cysts were prepared for the mass spectrometry analysis
following the same protocol as used for tachyzoites.

Lectin Pull-down

Cell Lysate Preparation

Parasite pellets, tachyzoites or bradyzoites, were resuspended in 10 mM tris
buffer (pH 7.5) with 150 mM NaCl and lysed utilizing French press at a pressure of
10,000 psi at medium setting. Protein concentration was determined by bicinchoninic
acid assay (BCA) according to manufacturer’s instructions. Calcium chloride and
manganese chloride to the final concentration of 1 mM, protease inhibitor as well as SDS
to the final concentration of 0.05 % were added to the cell lysate containing 1 mg of
protein, determined by BCA.
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Con A Column Preparation

Three Con A columns were prepared for each sample. Two milliliters of settled
Con A resin were placed in each plastic filter tube. Each resin was washed with 15 mL
of buffer containing 10 mM Tris (pH 7.5), 150 mM NaCl, 1 mM CaCl2 and 1mM MnCl2.

The Pull-down Procedure

Depending on the protein concentration, 3-4 mL of the parasite lysate were
applied to the first Con A column and incubated over night at 4 °C on the rotator. The
following day the flow through fraction from the first column was applied directly to the
freshly prepared second Con A column. To ensure all the flow through exited the first
column, 1.5 mL of column wash buffer was applied to the first column and the flow
through was caught in the second column until the flow stopped. The second column is
then placed on the rotator and incubated over night at 4 °C.
The first column was washed with 15 mL of column wash buffer. Four milliliters
of glycoprotein eluting solution were applied to the first column and incubated for 4
hours at room temperature on the rotator. Glycoproteins were eluted from the column
directly into two dialysis cups. To ensure all the Vector Labs elution solution exited the
first column, 1.5 mL of 25 mM ammonium bicarbonate buffer was applied to the column
and eluate was caught until the flow stopped. The eluate, divided in two dialysis cups,
was dialyzed for 24 hours against 9L of 25 mM ammonium bicarbonate buffer.
The following day the procedure was repeated for the second and third column.
The flow through fraction from the second column was applied directly to the freshly
prepared third Con A column. To ensure all the flow through exited the second column,
1.5 mL of column wash buffer was applied to the second column and the flow through
was caught in the third column until the flow stopped. The third column is then placed
on the rotator and incubated over night at 4 °C.
The second column was washed with 15 mL of the column wash buffer. Four
milliliters of glycoprotein eluting solution were applied to the second column and
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incubated for 4 hours at room temperature on the rotator. Glycoproteins were eluted
from the column directly into two dialysis cups. To ensure all the Vector Labs elution
solution exited the second column, 1.5 mL of 25 mM ammonium bicarbonate buffer was
applied to the column and eluate was caught until the flow stopped. The eluate, divided in
two dialysis cups, was dialyzed for 24 hours against 9 L of 25 mM ammonium
bicarbonate buffer.
The final day of the sample preparation glycoproteins from the third Con A
column were eluted. The flow through fraction was stored at -20 °C and the column was
washed with 15 mL of the column wash buffer. Four milliliters of glycoprotein eluting
solution were applied to the third column and incubated for 4 hours at room temperature
on the rotator. Glycoproteins were eluted from the column directly into two dialysis
cups. To ensure all the Vector Labs elution solution exited the third column, 1.5 mL of
25 mM ammonium bicarbonate buffer was applied to the column and eluate was caught
until the flow stopped. The eluate, divided in two dialysis cups, was dialyzed for 24 hours
against 9 L of 25 mM ammonium bicarbonate buffer.
Columns for all samples were made of fresh Con A resin to avoid sample
contamination.

Dialysis

Proteins were eluted from the Con A column with 4 mL of Vector Labs elution
solution. Since the capacity of the dialysis cup was only 2 mL, the eluate was placed into
2 dialysis cups with molecular weight cutoff limit of 3.5 kDa. Cups were placed on the
holder and the bottom was submerged in 1.5 L of stirred 25 mM ammonium bicarbonate
pH 8. Ammonium bicarbonate solution was replaced every 2 hours for four times. The
fifth solution was replaced after 4 hours. The sixth and final 1.5 L of ammonium
bicarbonate were left over night.
The following day, membranes on the bottom of dialysis cups was sealed with
parafilm to prevent leakage and sweating of the regenerated cellulose membrane and cups
were placed in their 50 mL test tube. Samples were now ready for digestion.
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Sample Preparation for Mass Spectrometric Analysis

Digestion of proteins was performed by adding trypsin solution directly to the
dialysis cup and incubating for 18 hours at 37 °C water bath. The amount of added
trypsin varied depending on the elution. To the eluate from the first column 10 µg of
trypsin was added, while 5 µg each were added to the second and third eluate.
After digestion, peptides were transferred to 1.5 ml Eppendorf tube and dried
using vacuum centrifuge. Peptides were reconstituted in 20 µL of a mobile phase
containing 94.9 % optima water, 5 % of optima acetonitrile and 0.1 % formic acid and
analyzed by Finnigan LCQ Deca ion trap mass spectrometer utilizing MuDPIT method.

Mass Spectrometry Analysis

Finnigan LCQ Deca ion trap mass spectrometer coupled with a LC Packings
Ultimate quaternary capillary LC system was used for the mass spectrometry analysis of
peptides.
Twenty microliters of digested glycoproteins obtained from the parasite lysate
were injected onto a laboratory fabricated fused silica capillary strong cation exchange
(Partisil SCX) column (350 μm I.D. x 5 cm, 10 μm particles). This column was directly
connected to laboratory fabricated fused silica capillary C18 column (350 μm I.D. x 15
cm, Microsphere 3.5 μm particles). Columns were packed using a stainless steel packing
cell. LC Packings Ultimate quaternary capillary LC system with a 20 µL injection loop
was used for the sample and mobile phase delivery at 4 µL/min.
Mobile phase A was comprised of 94.9% optima grade water, 5% optima grade
acetonitrile and 0.1% formic acid. Mobile phase B was comprised of 94.9% optima
grade acetonitrile, 5% optima grade water and 0.1% formic acid. Mobile phase C was
comprised of 300 mM ammonium acetate in optima grade water and mobile phase D was
the same composition as mobile phase A.
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Two-dimensional LC separation was performed with 12 isocratic salt elution
where following salt concentrations of 0 mM, 5 mM, 10 mM, 15 mM, 20 mM, 30 mM,
40 mM, 50 mM, 100 mM, 150 mM 225 mM and 300 mM were obtained by appropriately
mixing mobile phase C with mobile phase D. The 13th salt step was obtained by direct
injection of 20 µL of 3 M ammonium acetate.
Each salt elution was followed by a 110 min C18 reversed-phase gradient elution.
Mobile phase composition was first held at the appropriate mix of solvents C and D for
15 min (0 to 15 min), then was switched to solvent A for additional 2 min (15 to 17 min).
Gradient was linearly changed from 100% to 50% over 48 min (17 to 65 min) and from
50% to 20% over 20 min (65 to 85 min). Mobile phase composition was returned to
100% of solvent A in 5 min (85 to 90 min) and held at 100% for the next 20 min (90 to
110 min).
The voltage applied to electrospray source was 3.5 kV and 20 units of sheath gas
flow. I Inlet capillary was held at 35.0 V and 150 °C. Other parameters were as follows:
tube lens offset at -15.0 V, multipole 1 offset at -7.5 V, lens voltage at -50.0 V, multipole
2 offset at -13.0 V, multipole RF amplitude peak-peak at 400 V, entrance lens at -50.0 V
and trap DC offset at -10.0 V.
The mass spectrometer was operated in a data-dependent mode. Full scan from
m/z 200 to 2000 was acquired first. The most intense precursor ion was selected from the
previous full MS scan and submitted to collisional induced dissociation (CID) with an
activation Q of 0.250, activation time of 45 ms, and 35% normalized collision energy
(NCE). This was followed by a MS/MS scan between m/z 200 and 2000 of the most
intense ion of the previous full MS scan. The same procedure was performed for three
most intense ions that were excluded from further tandem experiments for one minutes.
Each analytical full scan was constructed as an average of 3 full scans, while each
analytical MS/MS scan was constructed as an average of 5 MS/MS scans.
A maximum ion trap injection time of 300 ms was used for the full scans and 500
ms was used for MS/MS scans. The automatic gain control (AGC) target for the full scan
was set to 2 x 107 and for MS/MS to 5 x 107.
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Protein Data Analysis

All 13 RAW files of a MuDPIT run were uploaded to the MASCOT daemon
software, combined as one file and searched against Toxoplasma gondii database
(http://toxodb.org/toxo/). Parameters were set as followed: the cleavage enzyme was
trypsin with three missed cleavage allowed. Peptide tolerance and the MS/MS tolerance
were set to 1.0 Da. Oxidized methionine was chosen as a variable modification.
MudPIT scoring was used and the requirement for positive protein identification
was bold red. This requires the protein hit to include at least one bold red peptide match
indicating that the peptide is the highest scoring match to the MS/MS spectra.
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Results and Discussion

Toxoplasma gondii is intracellular parasite that has several life stages. Two
stages that allow asexual expansion of the parasite are stages of tachyzoites and
bradyzoites. Tachyzoite is a rapidly growing stage responsible for dissemination during
acute infection while bradyzoite is a slow growing stage when tissue cysts are formed.
Utilizing methodology described in Chapter 2, a total of 394 N-glycosylated
proteins, from tachyzoites ME49 strain, were identified with 57 proteins identified in all
three replicates and 71 identified in at least two replicates (Figure 4.3).

Figure 4.3. Toxoplasma gondii ME49, tachyziotes, pull-down triplicate. Purple circle:
first pull-down replicate. Orange circle: second pull-down replicate. Yellow circle: third
pull-down replicate.

Triplicate analysis shows that majority of proteins is identified in one out of three
analyses. However, the closer look of the analyzed proteins reveals that the efficiency of
the pull-down method depends on molecular weight of the protein (Figure 4.4). This was
obtained by dividing all identified proteins in three groups: proteins identified in all three
replicates, proteins identified in two out of three replicates and proteins identified in at
least one replicate. Each group was further divided in three subgroups according to the
molecular weight of the protein: MW < 30 kDa, 30kDa < MW < 100 kDa and 100 kDa <
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MW. The number of proteins in each subgroup was normalized to the total number of
proteins in each group and expressed as a percentage. The result of this analysis shows
that proteins with molecular weight higher than 100 kDa are predominantly observed in
one out of three replicates while proteins with molecular weight lower than 30 kDa are
largely observed in all three replicates.

45%
40%
35%
30%
25%

< 30 kDa

20%

30 - 100 kDa
100 kDa <

15%
10%
5%
0%
in 3/3

in 2/3

in 1/3

Figure 4.4. Pull-down method dependence on molecular weight of the protein. X-axis
indicates in how many replicates were proteins of a certain molecular weight observed
out of three replicates. Y-axis indicates the percentage of proteins of a certain molecular

This observation points out the possibility of pull-down method refinement in the
future with the purpose to reduce the variability between replicates. To be more specific,
after cell lysis proteins could be separated according to their molecular weight utilizing
size-exclusion chromatography. However, discussion of results obtained in this
dissertation is based on proteins identified in all three replicates.
In general, interpretation of data from a subproteome obtained by the enrichment,
as in this case glycoproteome, will always suffer from some degree of contamination.
For example, a glycoprotein could be interacting with the organelle or transported
through the membrane at the time of extraction, and therefore, not be isolated by the
enrichment procedure. Or a non-glycosylated protein could be interacting with the
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glycoprotein, and therefore, be isolated with the enrichment procedure. For that reason,
reproducible sample preparation and replicate analysis is crucial.
Therefore, the discussion of tachyzoite glycoproteome focuses on 57 proteins
identified in all three replicates (table 3.1) indicating glycosylation as PTM. All other
proteins can be found in the tables A.1 and A.2 in the Appendix.

Invasion related glycosylated proteins

Dense granules, rhoptry and micronemes are secretory organelles specialized for
invasion and modification of the host cell. The entry of the parasite to the host cell starts
with the adhesion proteins secreted by micronemes, which assist rhoptry proteins to form
the moving junction resulting in parasitophorous vacuole.
Comparing the distribution of 57 identified proteins (table 4), obtained utilizing
the methodology described in chapter 2, 8 are associated rhoptry (ROP 1, ROP 2A, ROP
7, ROP 8, ROP 11, ROP 15, ROP 40 and RON 4) and 4 with dense granule organelle
(GRA 1, GRA 2, GRA 7, GRA 8). However, proteins associated with micronemes
proteins were not identified.
Part of the moving junction macromolecular complex is rhoptry neck protein
RON 4. RON 4 is exposed on the cytosolic side of the host cell during invasion and
binds C-terminal region of β-tubulin of the host early in invasion. [87] All rhoptry
proteins are associated with parasitophorus vacuole, either the ones injected through it
into the host cell during invasion or responsible for establishment of parasitophorus
vacuole.
Dense granule proteins also produce two types of proteins. One type is associated
with the formation of specialized tubules through which the parasite acquires nutrients
from the host. The other type is secreted into the host cell. [88]
Recently, a lot of effort has been put in evaluating vaccine antigens. [89, 90]
Some of the candidates, such as GRA 1, GRA 7, ROP 1 and ROP 2A were identified in
this analysis and listed in the table 4. All dense granule proteins induce a strong T and B
cell responses of the host, but all infectious stages of Toxoplasma gondii express GRA 7
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indicating it as a good candidate for the vaccine antigen. But even stronger immune
response was obtained when GRA 7 was coupled with ROP 1. [89] ROP 1 is penetrating
enhancing factor secreted into the nascent parasitophorous vacuole increasing the
efficiency of invasion. Another couple for the vaccine antigen is ROP 2A and SAG 1.
Glycosylation was found on ROP 2A, the protein that plays a role in association between
the parasitophorous vacuole and host cell mitochondria. [91]
Out of 10 dense granule proteins, where all are associated with parasitophorous
vacuole, GRA1, GRA2 and GRA8 were also identified utilizing method developed in
chapter 2 of this dissertation. GRA 1 and GRA 2 are part of the tubulovesicular
membranous network, the structure that allows small molecule trafficking. [92]
Serine-threonine phosphatase 2C (PP2C), found among glycosylated proteins,
targets the host nucleus during the invasion facilitated by rhoptry secretion. However,
the invasion completion is not required for delivery of this effector protein [93]
suggesting a possible epigenetic alteration of the host protein expression. Also, serinethreonine phosphatase 2C is found as part of the toxofilin–actin–PP2C complex where it
selectively dephosphorylates toxofilin at serine 53 promoting toxofilin’s affinity to Gactin. [94]
One more enzyme found among glycosylated proteins is protein disulfide
isomerase. Protein disulfide isomerase is localized on the surface of Toxoplasma gondii
where it regulates interactions between parasite and the host cell also making it a good
candidate for the vaccine antigen. [95]
Elongation factor 1-alpha (EF-1-ALPHA) is a putative protein in Toxoplasma
gondii but it is characterized in other members of phylum where it is also involved in
invasion pathway. [96]
Considering all these findings, it is interesting observation that initial adhesion of
the parasite to the host cell, regulated by micronemes proteins, does not involve
glycosylated proteins, while the subsequent steps such as formation of parasitophorous
vacuole as well as tubule formation proteins and secretory proteins are glycosylated
indicating those glycoproteins as a viable target for future studies in successful infection
prevention. Also, glycosylation is found in proteins not associated with invasion but with
maintenance of parasite within the host cell.
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Energy related glycosylated proteins

Several proteins associated with energy pathways were identified as glycosylated.
One of these is adenosylhomocysteinase. This is a putative protein with catalytic activity
and probably involved in energy transfer due to NAD-binding domains. Adenylate
kinase, another putative protein, is a phosphotransferase. Dihydrolipoyllysine-residue
succinyltransferase component of oxoglutarate dehydrogenase is acyltransferase that
takes part in tricarboxylic acid cycle. Glyceraldehyde-3-phosphate dehydrogenase
GAPDH1 is one of the key glycolytic enzymes. Another putative protein is GDP
mannose 4,6-dehydratase that catalyzes hydrolysis of GDP-mannose to GDP-4-dehydro6-deoxy-D-mannose. These findings indicate involvement of glycosylation in parasites
metabolic pathways.

DNA and translational machinery related glycosylated proteins

A number of DNA and translational machinery related proteins were identified as
glycosylated.
One of DNA related proteins is high mobility group (HMG) box domaincontaining protein class II, found in many eukaryotic chromosomal proteins and
transcription factors, is a non-histone chromosomal protein that binds to the bent or
distorted DNA.
SWI2/SNF2-containing PHD finger protein is a zinc-finger that exerts helicase
activity, DNA binding and ATP binding activity. PHD finger protein from other
organisms play a role in chromatin remodeling processes and histone acetylation. [97]
Histones are small, highly alkaline proteins responsible for packing DNA in
nucleosomes. Epigenetic gene regulation heavily relies on posttranslational
modifications of histones. Histones, H2A, H2B, and H4 are predicted for Toxoplasma
gondii. The study described in this dissertation reveals glycosylation on H2A1, H2AZ,
H4, and, surprisingly, H2Bb. H2B isoforms are expressed depending on the life cycle
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stage. H2Ba is expressed in tachyzoites while H2Bb is expressed only during the sexual
stage of the life cycle but not in tachyzoites nor bradyzoites. H4 is highly conserved
while H2A and H2B are prone to changes due to their exposed N-terminal tail. [98]
Proteins involved in translation seem to have a glycosylated member at every
stage of the process from initiation (eIF-5A, putative) through elongation (elongation
factor 2 family protein, putative) to regulation. Prolyl-tRNA synthetase (ProRS) and
tryptophanyl-tRNA synthetase (TrpRS2) are aminoacyl-tRNA synthetase located in
cytoplasm involved in regulation of translational fidelity and tryptophanyl-tRNA
aminoacylation respectively. Ribosomal protein RPL24 is a located on the surface of the
large subunit of a ribosome. RPL24 is involved in kinetics of peptide synthesis and
probably in interactions between the large and small subunits. Ribosomal protein RPS13
is essential for binding of the small ribosomal subunit to intersubunit of a ribosome.

Other identified glycosylated proteins

GTP-binding protein putative regulates G proteins (guanosine nucleotide-binding
proteins) that are known molecular switches.
Three chaperones were also identified as glycosylated proteins. Two of them are
heat shock homologs HSP 70 and HSP 90 and the third is chaperonin protein BiP. HSP
70 is highly expressed by the host cells where inhibits mitochondrial apoptosis of the
host. [99] HSP 90 chaperone machinery is involved in parasite development and can be
found in a complex with HSP 70. [100] Since HSP 70 and HSP 90 can form a complex
it is unclear if only one of the pair is glycosylated while the other is extracted only due to
complex formation. Chaperonin protein BiP is found in endoplasmatic reticulum where
it is involved in controlling protein folding and exit from the endoplasmatic reticulum.
[101]
Perhaps the most important finding in this study is the identification of
hypothetical proteins. In total 14 hypothetical proteins were identified not only in all
three replicates but also majority of them with the high score.
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Figure 4.5. Distribution of identified glycoproteins according to function.

To easier comprehend the current body of knowledge of glycosylation the results
are presented in a pie chart (Figure 4.5) having in mind the function of identified
glycoproteins. One third of N-glycosylated proteins are structural proteins mainly
involved in invasion and establishment of infection pointing to a group of proteins
already under consideration as a vaccine antigen candidates. At the same time a
prominent group of hypothetical proteins reveals that a field of glycoproteomics of
Toxoplasma gondii is still in its infancy offering a chance for improvement, which was
the goal of this dissertation.
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Table 4.1. Proteins identified in three out of three replicates.
protein
#
1
2

3
4
5

Mowse

queries

score

matched

41907

532

52

TGME49_220400

12922

46

17

TGME49_225050

64105

39

53

TGME49_224900

28560

100

25

TGME49_316400

50113

223

35

TGME49_230830 540153

35

195

TGME49_311720

73252

286

52

TGME49_227620

19804

554

78

TGME49_203310

25919

160

29

TGME49_254720

28628

34

6

TGME49_219550

50125

150

44

protein name

ID #

mass

actin ACT1 (ACT1)

TGME49_209030

actin depolymerizing
factor ADF (ADF)
adenosylhomocysteinase,
putative
adenylate kinase, putative
alpha tubulin TUBA1
(TUBA1)
ATPase family associated

6

with various cellular
activities (AAA) domaincontainig protein

7
8

9

10

chaperonin protein BiP
dense granule protein
GRA2 (GRA2)
dense granule protein
GRA7 (GRA7)
dense granule protein
GRA8 (GRA8)
dihydrolipoyllysineresidue

11

succinyltransferase
component of
oxoglutarate
dehydrogenase
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Table 3.1. (continued)
12

13

elongation factor 1-alpha
(EF-1-ALPHA), putative
GDP mannose 4,6dehydratase, putative

TGME49_286420

49005

1111

128

TGME49_238940

41717

53

19

TGME49_289690

53339

60

50

TGME49_214350

44547

38

26

TGME49_273760

72880

438

51

TGME49_288380

81932

150

44

glyceraldehyde-314

phosphate dehydrogenase
GAPDH1 (GAPDH1)

15

16

17

GTP-binding protein,
putative
heat shock protein HSP70
(HSP70)
heat shock protein HSP90
(HSP90)

18

histone H2A1

TGME49_261250

19546

321

62

19

histone H2AZ

TGME49_300200

15920

373

98

20

histone H2Bb

TGME49_251870

12575

197

55

21

histone H4

TGME49_239260

11439

397

41

TGME49_210408

10682
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75

HMG (high mobility
22

group) box domaincontaining protein

23

hypothetical protein

TGME49_294430 100125

53

58

24

hypothetical protein

TGME49_321680

40660

45

30

25

hypothetical protein

TGME49_297430

25336

70

20

26

hypothetical protein

TGME49_221470

61517

99

33

27

hypothetical protein

TGME49_275650 101158

92

50

28

hypothetical protein

TGME49_279420 144941

69

67

29

hypothetical protein

TGME49_212860 107698

53

62

30

hypothetical protein

TGME49_240080 122320

51

74
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Table 3.1. (continued)
31

hypothetical protein

TGME49_268760

31988

36

31

32

hypothetical protein

TGME49_268260

86736

51

60

33

hypothetical protein

TGME49_223640 180412

35

89

34

hypothetical protein

TGME49_310970 370390

40

234

35

hypothetical protein

TGME49_315570

140

26

36

hypothetical protein

TGME49_248160 122417

52

71

TGME49_268920

50014

36

33

TGME49_205558

20507

66

21

TGME49_219850

93478

74

73

TGME49_211680

52801

247

32

TGME49_227810

58034

97

27

TGME49_291960

57947

160

35

TGME49_229010 107174

65

36

TGME49_309590

47994

259

56

TGME49_211290

36588

146

35

37

38

39

40

inositol polyphosphate
kinase
NAC domain-containing
protein
prolyl-tRNA synthetase
(ProRS)
protein disulfide
isomerase

9273

rhoptry kinase family
41

protein ROP11
(incomplete catalytic
triad) (ROP11)
rhoptry kinase family

42

protein ROP40
(incomplete catalytic
triad) (ROP40)

43

44

45

rhoptry neck protein
RON4 (RON4)
rhoptry protein ROP1
(ROP1)
rhoptry protein ROP15
(ROP15)
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Table 3.1. (continued)
46

47

48

49

50

51

52

rhoptry protein ROP2A
(ROP2A)
rhoptry protein ROP7
(ROP7)
rhoptry protein ROP8
(ROP8)
ribosomal protein RPL24
(RPL24)
ribosomal protein RPS13
(RPS13)
serine-threonine
phosophatase 2C (PP2C)
SWI2/SNF2-containing
PHD finger protein

TGME49_215785

49154

184

41

TGME49_295110

63394

52

18

TGME49_215775

65912

126

41

TGME49_244320

32693

35

21

TGME49_270380

17176

84

22

TGME49_231850

36790

195

22

TGME49_236970 277892

35

160

TGME49_205470 106571

104

62

TGME49_251810

17468

323

25

TGME49_288360

77057

67

46

TGME49_270250

20225

52

10

TGME49_270595 849189

46

320

translation elongation
53

factor 2 family protein,
putative

54

55

56

57

translation initiation factor
eIF-5A, putative
tryptophanyl-tRNA
synthetase (TrpRS2)
dense granule protein
GRA1 (GRA1)
UBA/TS-N domaincontaining protein
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Bradyzoites related glycosylated proteins

The analysis of protein glycosylation of bradyzoites (table 3.2) mostly resulted in
identification of 28 proteins out which 9 are hypothetical and 6 are putative. Identified
proteins are mainly enzymes associated with translation and transcription and protein
domains. However, very little is known about the role of these proteins in Toxoplasma
gondii and their function, structure or location is mostly inferred by homology.
For example, DnaJ domain-containing protein is identified but its function is not
known. However, since DnaJ proteins are highly conserved in eukaryotes their function
can be inferred for Toxoplasma gondii. DnaJ in complex with HSP 40 play crucial roles
in protein translation, folding, unfolding, translocation, and degradation.
Transcription is a complex process that involves many enzymes as herein
identified UvrD/REP helicase domain-containing protein involved in DNA damage and
repair. Transcription is initiated by RNA polymerase II apparatus but the role of
identified mediator complex subunit MED14 is not explained for Toxoplasma gondii. In
humans this complex is a component of the mediator complex responsible for
transcription regulation of almost all RNA polymerase II-dependent genes. [102]
Epsilon subunit of eukaryotic initiation factor-2B is identified as putative but it has an
important role in regulating mRNA translation in eukaryotes. TrmH family of proteins is
involved in tRNA recognition and one of the members, RNA methyltransferase, is also
identified. [103]
Mitochondrial proteins responsible for protein import are found in the earliest
eukaryotes. For that reason, even though mitochondrial inner membrane translocase
subunit TIM17 is identified in this study as putative, its function can be narrowed down
to either facilitator of the translocation of proteins across the inner membrane or
facilitator of the insertion of proteins into the inner mitochondrial membrane. [104]
Reversible protein phosphorylation is used for cellular information processing and
has to be tightly controlled. That is easier achieved by formation of complexes of kinases
and other proteins. One of such complexes is CMGC kinase group, identified here as
putative. [105]
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As a part of S8 peptidase family, subtilisin SUB2 is a protease that contains a
catalytic triad of serine, aspartate and histidine. [106]
Sec1 family protein is a part of Sec1/Munc18 (SM) family proteins that are
essential for every vesicle fusion pathway. [107]
GYF domains are present in most eukaryotic species and recognize proline-rich
sequences. Even though not fully elucidated for Toxoplasma gondii, GYF domaincontaining protein is identified in this study. [108]
WD domain is found as a repeat in a large number of diverse eukaryotic proteins
but what they have in common is folding into beta propeller that serves as a part of the
platform used for reversible assembly of many protein complexes in almost all the major
pathways. G-beta repeat-containing protein is identified.
Myosin K, identified in this study, is a part of motility system of Toxoplasma
gondii, utilized for invasion as well as the escape from the host cells but also for general
motility. [109]
Structural proteins such as clathrin and trichohyalin are also identified in this
study but as putative. In humans clathrin is predominant component of polyhedral coat of
coated pits and vesicles. Components of clathrin are 3 heavy chains and 3 light chains.
Trichohyalin is responsible for organizing the intermediate filaments in human hair
follicle inner root giving the shape to the hair fiber. [110]
Even more importantly, out of 28 identified proteins 9 are hypothetical leaving a
large part of glycosylated proteins under mysterious veil impossible even to infer.
Interestingly one of the hypothetical proteins was identified with the highest score
comparing to all other identified proteins.
However, one should keep in mind that these results are obtained from only one
sample and not confirmed with replicates due to the lack of material. This sample was
obtained from brains of 26 mice with the total number of 7 x 104 cysts. Total amount of
protein was 1.6 mg and that amount was too small to divide in replicates.
Also, results in the table 4.2 show low scores for the most proteins identified by
the Mascot search engine. Even though all proteins above the threshold are identified
with 95% confidence, proteins close to the threshold still have a high probability of being
a random sequence.
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Putative proteins recognized in other organisms need to be further confirmed and
characterized by studying mutant parasites lacking the relevant gene and identifying the
proteins involved in their pathways.

Conclusion

Even though ME49 strain is most prevalent in clinically diagnosed cases of
toxoplasmosis, most proteomic studies are performed on RH strain because large
quantities are easily obtained in tissue culture. Moreover, bradyzoite stage of parasites
life cycle, which develop in mice brains after approximately two to four weeks, is
significantly less studied comparing to rapidly growing tachyzoite stage. Considering all
this, it is not surprising that the glycosylation machinery and its effects in Toxoplasma
gondii are still largely unknown. To that end, the aim of this study is to contribute to
current knowledge database by identifying the possible candidates for the future studies.
In total 394 glycosylated tachyzoite proteins and 28 glycosylated bradyzoite
proteins were identified utilizing the method developed in the chapter 2 of this
dissertation. Due to sample availability tachyzoite proteins were analyzed in triplicate
and 57 out of 394 were identified in all replicates suggesting glycosylation as their posttranslational modification. However, bradyzoites were studied utilizing only one sample
due to the time required for their generation and the cost. Nevertheless, 28 proteins were
identified. The lower number does not necessarily indicate low glycosylation but could
also be due to low sample amount where majority of proteins are below the identification
threshold of mass spectrometer. For that reason, more experimental proof is required.
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Table 4.2. Proteins identified in tissue cysts.
protein
#
1
2

matched

122417

126

110

TGME49_229310 464457

41

165

TGME49_206415 262859

38

169

TGME49_271060

72640

37

47

TGME49_242790 200679

37

102

TGME49_313310

65713

35

60

TGME49_239260

11439

35

20

TGME49_219218 175383

35

74

TGME49_319600

98566

35

68

TGME49_253020

51621

34

26

TGME49_277550 342488

34

140

TGME49_290950 194501

34

66

TGME49_213060 328236

34

127

TGME49_272640

92848

34

75

TGME49_312220

22612

33

21

hypothetical protein

TGME49_248160

mediator complex subunit
MED14 (MED14)

4

Sec1 family protein

5

trichohyalin, putative
DnaJ domain-containing
protein

7

histone H4

8

hypothetical protein

10

score

mass

myosin K

9

queries

ID #

3

6

Mowse

protein name

alpha-tubulin Nacetyltransferase, putative
hypothetical protein
UvrD/REP helicase

11

domain-containing
protein

12

13

clathrin heavy chain,
putative
WD domain, G-beta
repeat-containing protein
eukaryotic initiation

14

factor-2B, epsilon
subunit, putative
mitochondrial inner

15

membrane translocase
subunit TIM17, putative
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Table 3.2. (continued)
16

DUF367 domaincontaining protein

TGME49_204540

63641

33

50

17

CMGC kinase, putative

TGME49_250850 286625

33

123

18

subtilisin SUB2 (SUB2)

TGME49_314500 141581

33

77

19

hypothetical protein

TGME49_224830 121076

33

68

TGME49_272040 358195

33

91

TGME49_251180

29178

33

20

TGME49_298610 237893

33

132

20
21
22

WD domain, G-beta
repeat-containing protein
KRUF family protein
GYF domain-containing
protein

23

hypothetical protein

TGME49_306440

96284

33

37

24

hypothetical protein

TGME49_231815 431546

33

240

25

hypothetical protein

TGME49_210700 926533

32

420

26

hypothetical protein

TGME49_259870 230595

32

128

27

hypothetical protein

TGME49_233430 410963

32

207

TGME49_216390

32

46

28

RNA methyltransferase,
TrmH family protein

89523
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CHAPTER 5
CONCLUSION

Toxoplasma gondii is intracellular parasite that has several life stages. Humans
are impacted by the two stages that allow asexual expansion of the parasite: tachyzoite
and bradyzoite stages. Tachyzoite is a rapidly growing stage responsible for
dissemination during acute infection while bradyzoite is a slow growing stage when
tissue cysts are formed.
Acute infection invokes the response of the host’s immune system and can be
treated with combinations of antibiotics and antimalarial medications. Even though a
large majority of tachyzoites are eliminated this way, a very few are required for the
establishment of bradyzoites enclosed within the tissue cysts and responsible for the
chronic phase of infection when the parasite becomes invisible for the host’s immune
system. This, so called, "dormant phase" has only recently been discovered to interfere
with the host’s behavioral changes, most probably by altering neurotransmitter signal
transduction and increasing the production of dopamine. [83]
Although there are three types of lineages of Toxoplasma gondii (type I (RH and
GT-1 strains), type II (ME49 strain) and type III (VEG strain)), the clinical cases of
toxoplasmosis are most commonly due to type II (ME49) isolates. ME49 strain, while
significantly less virulent in mice, readily forms the cysts. [111] For that reason ME49 is
chosen for the study described in this dissertation.
Inferring form the genome of Toxoplasma gondii, it is believed that the parasite
can express about 6500 proteins. But 72 already identified proteins have no identified
transcripts. This can be attributed to posttranslational modifications that often have a
functional significance and can help to understand the biology of the parasite. [112]
However, glycosylation of the proteome of Toxoplasma gondii is still largely unknown
with even more scarce evidence of N-glycosylation. Studies performed on RH strain of
the parasite identified 26 N-glycosylated proteins indicating involvement of Nglycosylation in gliding motility and host cell invasion. [85] Three of those 26
glycoproteins were identified utilizing method developed in this dissertation. Two
rhoptry proteins of tachyzoites are associated with the invasion of the host cell, but the
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third protein DnaJ was identified only in bradyzoites that were not analyzed in above
mentioned study.
However, one striking structural difference between tachyzoites and bradyzoites
raises the question if the glycosylation plays a significant role in bradyzoite stage of
parasite’s life. That difference is the location of Golgi complex.
In bradyzoites both endoplasmatic reticulum and Golgi complex are located near
the basal end of the parasite. However, in tachyzoites Golgi complex is located near to
the apical end with numerous organelles separating it from endoplasmatic reticulum.
[83] Considering that N- and O-glycosylation take place in both endoplasmatic reticulum
and Golgi complex, it would be hard to comprehend the significance of organelle
separation if glycosylation played an important role in tachyzoites. However,
bradyzoites, developed from tachyzoites in the later stage of parasites life, have Golgi
complex and endoplasmatic reticulum in close proximity. One could speculate the
importance of this movement and wonder if N- and/or O-glycosylation play a significant
role in cyst formation or maintenance.
In general, the array of glycans displayed on the surface of various viruses (HIV)
or even cell types (blood group) can silence or induce the immune response of the host.
Tachyzoite stage of Toxoplasma gondii is recognized by the host and induces the immune
response that can be treated but bradyzoites are not recognized. Current treatment of
tachyzoites is not efficient enough and some of the surviving tachyzoites evolve into
bradyzoite stage. It is speculated that the parasite recruits some of the host proteins and
uses them for its own growth and maintenance but that could also be the case with the
glycans. If the host’s glycans are displayed at the surface of the cyst the immune system
would not recognize it as a foreign object.
Figure 4.2, in chapter 4, represents the bradyzoites containing tissue cyst stained
with two lectins, DBA and Con A. DBA binds to N-acetyl-D-galactosamine (GalNAc)
residues typical for O-linked glycoproteins but not found in N-linked glycoproteins,
while Con A specifically recognizes the trimannoside core of N-linked glycans. It is
obvious from the figure 4.2 that O-linked glycans are not observed anywhere within the
cyst but are abundantly present on the cyst wall. If the O-linked glycans were produced
or transported in any vesicle within the cyst the green stain would be obvious, but it is
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not. This raises the question if O-linked glycans are recruited from the host thus making
a parasite invisible to the host’s immune system.
Glycosylation plays a crucial role in cell signaling. Utilizing the method
described in this dissertation, N-glycosylated proteins are identified in both tachyzoites
and bradyzoites but only one glycoprotein is found in both groups and it is not yet
annotated. Considering parasite’s different morphology and the growth rate in these two
life stages, different signaling pathways are easily envisioned. However, the glycoprotein
present in the both groups could be the key to understanding of the transition from
tachyzoites to bradyzoites and provide the good target to prevent cyst formation and
eliminate the parasite before it becomes invisible to the host’s immune system.
In my opinion the key to successful eradication of infection caused by
Toxoplasma gondii lays not so much in the recognition of the differences between
tachyzoites and bradyzoites but their similarities. If the tissue cysts recruit and display on
their surface components derived from the host’s organism, damaging the tissue cyst
would inevitably damage the host as well. However, if one would identify components
within the tachyzoites, while the parasite is still visible to the immune system and thus
different then the host, then those components could possibly become the target for the
treatment that would be least damaging for the host. It would be fortunate to find such
components among the proteins that are unique to the parasite but not present in the host.
It was such notion that drove the development of this dissertation.
Due to the growing body of evidence pointing out the importance of glycosylation
of tachyzoites, the methods described in this dissertation were developed in an effort to
provide an improvement of purification and enrichment of glycoproteins that
subsequently could point out the candidate glycoproteins for future studies that will shed
the light on the biology of Toxoplasma gondii and thus help develop means for
toxoplasmosis eradication.
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APPENDIX

Table A.1. Proteins identified in two out of three replicates.
protein
#
1

protein name
AMP-binding enzyme domaincontaining protein

ID #

mass

Mowse queries
score matched

TGME49_247760 86986

40

37

2

calmodulin, putative

TGME49_269442 9780

75

10

3

cyclin protein

TGME49_293280 273014

56

150

TGME49_313600 161510

32

108

TGME49_216860 49113

51

24

TGME49_286450 12838

92

11

TGME49_259550 82684

60

28

TGME49_300140 44039

36

18

TGME49_250770 46673

58

47

TGME49_248340 25997

41

22

4

5

6
7
8

9

10

DDHD domain-containing
protein
DEAD (Asp-Glu-Ala-Asp) box
polypeptide DDX39 (DDX39)
dense granule protein GRA5
(GRA5)
dihydropteroate synthase
elongation factor 1-gamma,
putative
eukaryotic initiation factor-4A,
putative
GTP-binding nuclear protein
ran/tc4

11

heat shock protein 90, putative

TGME49_244560 96822

79

62

12

histone H2Ba

TGME49_305160 12602

197

55

13

histone H2Bv

TGME49_209910 13732

197

44

14

histone H3

TGME49_261240 15402

91

52

15

hypothetical protein

TGME49_232120 222553

34

73

16

hypothetical protein

TGME49_312420 117806

44

50

17

hypothetical protein

TGME49_278960 58350

34

30
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Table A.1. (continued)
18

nucleosome assembly protein
(nap) protein

TGME49_244110 48586

38

25

19

PEP-carboxykinase I

TGME49_289650 75342

84

38

20

rhoptry protein ROP5 (ROP5)

TGME49_308090 61101

71

57

TGME49_263700 16301

53

33

TGME49_291850 6600

66

13

TGME49_307840 23344

37

21

TGME49_209950 47699

43

47

TGME49_291890 48629

37

23

TGME49_318590 70666

57

27

TGME49_247550 60913

107

49

TGME49_275630 185550

39

64

histone H3 centromeric CENH3 TGME49_225410 23282

47

39

21

22

23
24
25

26

27

ribosomal protein RPS14
(RPS14)
ribosomal protein RPS30
(RPS30)
SF-assemblin/beta giardin
protein
thioredoxin, putative
microneme protein MIC1
(MIC1)
MRP family domain-containing
protein
heat shock protein HSP60
(HSP60)
HECT-domain (ubiquitin-

28

transferase) domain-containing
protein

29
30

histone H3.3

TGME49_218260 15413

91

51

31

hypothetical protein

TGME49_321410 212035

38

124

32

hypothetical protein

TGME49_221220 213039

35

100

33

hypothetical protein

TGME49_297210 444121

32

216

34

hypothetical protein

TGME49_215980 24466

34

16

TGME49_310190 317227

32

86

TGME49_226540 54688

93

59

35
36

PIK3R4 kinase-related protein
(incomplete catalytic triad)
protein kinase
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Table A.1. (continued)
regulator of chromosome
37

condensation (RCC1) repeat-

TGME49_310290 80702

40

74

TGME49_295125 42389

66

20

TGME49_215470 24603

33

20

TGME49_271050 19106

59

6

TGME49_312630 286215

69

185

TGME49_272710 356669

43

242

various cellular activities (AAA) TGME49_242625 976079

36

505

TGME49_203840 196955

34

149

TGME49_285350 25051

37

27

TGME49_235920 514463

49

335

TGME49_226410 36049

56

23

TGME49_276180 296268

33

151

TGME49_227970 25188

66

14

containing protein
38
39

40
41
42

rhoptry protein ROP4 (ROP4)
ribosomal protein RPL10A
(RPL10A)
SAG-related sequence SRS34A
(SRS34A)
anonymous antigen-1, putative
AP2 domain transcription factor
AP2VIII-4 (AP2VIII4)
ATPase family associated with

43

subfamily protein
44
45
46

DEAD/DEAH box helicase
domain-containing protein
dynein light chain, putative
dynein, axonemal, heavy chain 2
family protein
EF-1 guanine nucleotide

47

exchange domain-containing
protein

48

49

histone acetyltransferase
TAF1/250
histone family DNA-binding
protein

50

histone H2AX

TGME49_261580 14510

35

28

51

hypothetical protein

TGME49_221280 439285

33

284

52

hypothetical protein

TGME49_240060 88532

69

48
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Table A.1. (continued)
53

hypothetical protein

TGME49_239410 256130

39

198

54

hypothetical protein

TGME49_205130 518657

37

277

55

hypothetical protein

TGME49_203980 201277

44

78

56

hypothetical protein

TGME49_230350 138895

35

79

57

hypothetical protein

TGME49_228070 441563

37

240

58

hypothetical protein

TGME49_315610 15971

132

48

59

hypothetical protein

TGME49_316470 363875

36

148

60

hypothetical protein

TGME49_276860 55516

34

37

NAC domain-containing protein TGME49_257090 38782

56

26

TGME49_280380 61836

47

42

TGME49_260600 172516

37

81

TGME49_254440 17821

38

14

ribosomal protein RPP2 (RPP2) TGME49_309810 11768

43

21

TGME49_205340 15399

67

9

TGME49_218580 310819

73

111

TGME49_262620 31760

58

63

TGME49_238500 19504

39

9

TGME49_214270 126067

35

91

TGME49_242830 223762

35

107

61
62

63

64
65
66
67
68

69

70

71

poly(ADP-ribose)
glycohydrolase
Pumilio-family RNA binding
repeat-containing protein
ribosomal protein RPL12
(RPL12)

ribosomal protein RPS12
(RPS12)
RNA methyltransferase
RNA recognition motifcontaining protein
SAG-related sequence SRS22F
(SRS22F)
translation initiation factor IF-2,
putative
XRN 5'-3' exonuclease Nterminus protein
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Table A.2. Proteins identified in one out of three replicates.
protein
#

protein name

ID #

2-oxo acid dehydrogenases
1

acyltransferase (catalytic domain)

TGME49_31
9920

domain-containing protein
2

3-hydroxyisobutyrate

TGME49_26

dehydrogenase

3430

5'-3' exonuclease, N-terminal
3

resolvase family domain-containing

TGME49_28
4010

protein
4

ABC transporter, putative

5

ABC1 family protein

6

7

8

9

10

11

12

TGME49_20
8050
TGME49_21
3620

acetyltransferase, GNAT family

TGME49_30

protein

5450

adaptin c-terminal domain-

TGME49_27

containing protein

2600

AMP-binding enzyme domain-

TGME49_31

containing protein

0080

AMP-binding enzyme domain-

TGME49_21

containing protein

9230

AP2 domain transcription factor

TGME49_29

AP2III-4 (AP2III4)

9020

AP2 domain transcription factor

TGME49_28

AP2V-2 (AP2V2)

5895

arginyl-tRNA synthetase

TGME49_27
0690

109

Mowse

queries

score

matched

70289

34

35

34159

35

26

124798

34

75

381288

39

224

211215

41

135

56862

40

36

182951

32

93

87847

42

46

87016

36

34

171537

38

112

365853

38

167

130254

34
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mass

Table A.2. (continued)
13

argonaute AGO (AGO)

14

beta tubulin

15

beta-tubulin, putative

TGME49_31
0160
TGME49_26
6960
TGME49_22
1620

bifunctional GMP
16

TGME49_23

synthase/glutamine

0450

amidotransferase protein
17

18

19

20

21

22

23

Brf1p family coiled coil protein

TGME49_23
2440

calcium dependent protein kinase

TGME49_22

CDPK7 (CDPK7)

8750

calcium dependent protein kinase

TGME49_29

CDPK8 (CDPK8)

2055

cAMP-dependent protein kinase

TGME49_24

regulatory subunit

2070

cell-cycle-associated protein kinase, TGME49_28
putative
ClpB, putative

1450
TGME49_27
5690

cold-shock DNA-binding domain- TGME49_32
containing protein

24

CRIPT, putative

25

cyclin protein

26

cyclophilin

0600
TGME49_25
0350
TGME49_29
3280
TGME49_22
1210

110

105190

34

75

50073

61

44

50037

61

45

62294

34

41

54044

34

76

219083

34

95

161419

36

77

42796

35

42

50168

36

44

114549

36

80

23060

87

21

10076

32

7

273014

68

181

19604

48

24

Table A.2. (continued)
27

28

29

30

31

32

TGME49_20

cyclophilin precursor

5700

D-3-phosphoglycerate

TGME49_23

dehydrogenase

9820

DEAD/DEAH box helicase domain- TGME49_26
containing protein

4160
TGME49_29

DEAD-family helicase

8020

dense granule protein GRA3

TGME49_22

(GRA3)

7280

DNA-dependent RNA polymerase TGME49_24
(POLRMT)

6060

33

DnaJ family chaperone, putative

34

DnaK family protein

35

elongation factor TS protein

36

37

TGME49_31
1240
TGME49_22
6830
TGME49_20
9010

endonuclease/exonuclease/phosphat TGME49_23
ase domain-containing protein

8400

endonuclease/exonuclease/phosphat TGME49_25
ase family protein

9560
TGME49_26

38

enolase 1

39

enolase 2

40

ERCC4 domain-containing protein

8860
TGME49_26
8850
TGME49_30

111

5310

38196

49

31

65193

58

3

120180

33

62

130966

33

80

23875

58

16

232348

37

123

47448

33

39

103191

41

49

52348

37

26

290205

40

141

164511

42

54

48341

36

25

52113

36

32

223459

40

136

Table A.2. (continued)
41

42

43

44

45

46

47

48

49

50

ethylene-responsive RNA helicase, TGME49_31
putative

3240

eukaryotic aspartyl protease

TGME49_20

superfamily protein

9620

eukaryotic initiation factor-2

TGME49_23

gamma, putative

5970

eukaryotic translation initiation

TGME49_31

factor 3 subunit 7, putative

7720

Fe-S metabolism associated

TGME49_27

domain-containing protein

7010

FHA domain-containing protein

7600

FUSE-binding protein 2 / KH-type TGME49_21
splicing regulatory protein (FUBP2)

6670

glucose-6-phosphate 1-

TGME49_29

dehydrogenase

4200

glutamine synthetase, type I,

TGME49_27

putative

3490

glutaminyl-tRNA synthetase

TGME49_21

(GlnRS)

7460

glycine cleavage T-protein
51

TGME49_26

(aminomethyl transferase) domain-

TGME49_28
3820

containing protein

TGME49_24

52

GTPase RAB7 (RAB7)

53

guanylyl cyclase

54

HEAT repeat-containing protein

8880
TGME49_25
4370
TGME49_24

112

4040

85533

34

43

43488

33

16

50508

39

26

68766

39

62

36177

32

31

84416

33

47

100093

43

99

62736

39

47

65146

35

49

95526

34

57

195707

36

96

47712

35

33

477032

39

161

132694

32

39

Table A.2. (continued)
55

HEAT repeat-containing protein

56

heat shock protein

9180
TGME49_25
1780

HECT-domain (ubiquitin57

TGME49_22

TGME49_29

transferase) domain-containing

5710

protein
58

59

60

61

TGME49_20

helicase, putative

9770

helix-hairpin-helix motif domain-

TGME49_28

containing protein

5490

histone lysine methyltransferase,

TGME49_20

SET, putative

1250

HMG (high mobility group) box

TGME49_21

domain-containing protein

9828

62

hypothetical protein

63

hypothetical protein

64

hypothetical protein

65

hypothetical protein

66

hypothetical protein

67

hypothetical protein

68

hypothetical protein

TGME49_32
6600
TGME49_29
4860
TGME49_29
5370
TGME49_29
3252
TGME49_29
3560
TGME49_20
9470
TGME49_22
0890

113

136163

39

595

78250

38

85

851243

46

475

150821

35

68

117256

37

64

177893

39

114

11381

50

34

17775

32

46

254850

38

109

29729

32

21

166690

41

64

229122

37

66

57616

39

18

51195

36

28

Table A.2. (continued)
69

hypothetical protein

70

hypothetical protein

71

hypothetical protein

72

hypothetical protein

73

hypothetical protein

74

hypothetical protein

75

hypothetical protein

76

hypothetical protein

77

hypothetical protein

78

hypothetical protein

79

hypothetical protein

80

hypothetical protein

81

hypothetical protein

82

hypothetical protein

TGME49_22
1560
TGME49_22
2060
TGME49_22
2250
TGME49_25
3990
TGME49_29
9270
TGME49_29
9130
TGME49_27
6200
TGME49_21
1700
TGME49_26
5470
TGME49_26
5280
TGME49_26
4890
TGME49_27
9380
TGME49_28
9520
TGME49_28
9970

114

58420

50

54

103670

34

70

167959

36

109

231484

41

101

119375

34

65

346626

38

210

448604

36

317

273962

35

124

43627

36

39

133185

37

66

199927

36

106

34769

73

24

355979

39

137

24448

53

24

Table A.2. (continued)
83

hypothetical protein

84

hypothetical protein

85

hypothetical protein

86

hypothetical protein

87

hypothetical protein

88

hypothetical protein

89

hypothetical protein

90

hypothetical protein

91

hypothetical protein

92

hypothetical protein

93

hypothetical protein

94

hypothetical protein

95

hypothetical protein

96

hypothetical protein

TGME49_29
0310
TGME49_29
0620
TGME49_29
2360
TGME49_26
7670
TGME49_21
3635
TGME49_28
6510
TGME49_28
5820
TGME49_24
0980
TGME49_24
3310
TGME49_24
3780
TGME49_24
4120
TGME49_23
9340
TGME49_20
5320
TGME49_20
3362

115

200813

34

138

296416

37

187

117449

35

47

90813

35

51

325486

33

145

53152

35

20

19055

35

21

151943

33

83

132517

32

82

91568

42

47

248641

34

194

211263

36

145

70849

33

36

24667

36

16

Table A.2. (continued)
97

hypothetical protein

98

hypothetical protein

99

hypothetical protein

100

hypothetical protein

101

hypothetical protein

102

hypothetical protein

103

hypothetical protein

104

hypothetical protein

105

hypothetical protein

106

hypothetical protein

107

hypothetical protein

108

hypothetical protein

109

hypothetical protein

110

hypothetical protein

TGME49_20
3090
TGME49_20
2170
TGME49_26
1740
TGME49_26
1390
TGME49_25
8670
TGME49_25
8420
TGME49_25
8170
TGME49_26
3200
TGME49_26
3080
TGME49_23
0950
TGME49_23
1200
TGME49_22
9390
TGME49_22
9750
TGME49_26
9413

116

60624

34

63

94060

33

32

14158

40

10

28567

34

14

187479

41

94

259194

35

101

43915

35

27

118612

35

61

14407

91

10

240359

37

91

298665

37

141

103131

39

40

146074

33

83

11746

41

6

Table A.2. (continued)
111

hypothetical protein

112

hypothetical protein

113

hypothetical protein

114

hypothetical protein

115

hypothetical protein

116

hypothetical protein

117

hypothetical protein

118

hypothetical protein

119

hypothetical protein

120

hypothetical protein

121

hypothetical protein

122

hypothetical protein

123

hypothetical protein

124

hypothetical protein

TGME49_26
8950
TGME49_23
0180
TGME49_22
6690
TGME49_22
6320
TGME49_22
5380
TGME49_22
5130
TGME49_22
8630
TGME49_22
4320
TGME49_22
3760
TGME49_22
3725
TGME49_22
3500
TGME49_23
4250
TGME49_23
4590
TGME49_23
5580

117

60196

35

25

57330

34

26

113185

37

65

73663

36

22

51498

36

56

148061

40

74

34812

115

23

262381

39

156

168702

32

87

449056

32

188

120960

34

66

248625

35

182

30345

38

28

79102

33

62

Table A.2. (continued)
125

hypothetical protein

126

hypothetical protein

127

hypothetical protein

128

hypothetical protein

129

hypothetical protein

130

hypothetical protein

131

hypothetical protein

132

hypothetical protein

133

hypothetical protein

134

hypothetical protein

135

hypothetical protein

136

hypothetical protein

137

hypothetical protein

138

hypothetical protein

TGME49_23
6800
TGME49_23
7195
TGME49_22
8065
TGME49_21
4950
TGME49_21
5030
TGME49_31
0790
TGME49_31
1270
TGME49_31
2500
TGME49_31
2580
TGME49_31
2905
TGME49_31
3340
TGME49_31
3430
TGME49_24
6190
TGME49_24
6580

118

52349

36

22

99915

44

45

10166

34

6

21501

36

2

199439

33

62

24708

51

28

203341

34

108

169890

39

113

96685

34

48

261708

41

202

161141

36

187

593550

43

219

530021

37

228

42820

35

27

Table A.2. (continued)
139

hypothetical protein

140

hypothetical protein

141

hypothetical protein

142

hypothetical protein

143

145

kelch repeat-containing protein

146

kinesin, putative

149

TGME49_30
7860
TGME49_25
0090
TGME49_21
9640

domain-containing protein
kelch repeat-containing protein

148

7520

Kazal-type serine protease inhibitor TGME49_22

144

147

TGME49_24

4080
TGME49_26
4940
TGME49_22
9290
TGME49_28
6660

lactate dehydrogenase LDH1

TGME49_23

(LDH1)

2350

lactate dehydrogenase LDH2

TGME49_29

(LDH2)

1040

leucine rich repeat-containing

TGME49_26

protein

2530

150

leucyl aminopeptidase LAP (LAP)

151

lipase

152

TGME49_29
0670
TGME49_26
9300

long-chain fatty acid CoA ligase,

TGME49_24

putative

3800

119

26535

34

9

434056

42

235

88129

35

52

197263

34

153

214943

33

83

214243

33

81

104328

37

39

76150

36

30

35548

32

56

35334

43

44

108056

34

29

83236

34

68

126439

35

82

83507

49

53

Table A.2. (continued)
153

mannosyl-oligosaccharide

TGME49_24

glucosidase

2020

154

MC family transporter, putative

155

Met-10+ like-protein

156

methyltransferase MTA70, putative

157

microneme protein MIC2 (MIC2)

158

MoaC family protein

159

Mpv17 / PMP22 family protein

160

162

myosin D

165

166

TGME49_24
3280
TGME49_21
7350
TGME49_20
1780
TGME49_24
0930
TGME49_27
3290

containing protein
myosin A

164

8790

Myb family DNA-binding domain- TGME49_32

161

163

TGME49_20

1450
TGME49_23
5470
TGME49_26
3180

Nin one binding (NOB1) Zn-ribbon TGME49_21
family protein

8570

non-specific serine/threonine protein TGME49_26
kinase

8370

Not1 N-terminal domain, CCR4-Not TGME49_23
complex component protein
notchless, putative

3020
TGME49_21
5740

120

151503

33

47

33687

53

26

98907

35

74

87997

39

49

82633

34

43

41013

35

38

93582

33

54

437016

33

237

93319

36

52

91051

36

82

61202

43

37

904528

36

419

83853

34

34

57710

59

23

Table A.2. (continued)
oxidoreductase, short chain
167

dehydrogenase/reductase family

TGME49_31
3050

protein
168

PCI domain-containing protein

169

PCI domain-containing protein

170

PDI family protein

171

172

TGME49_29
2220
TGME49_21
7820
TGME49_23
2410

peptidase M16 family potein,

TGME49_23

putative

6210

peptidase M16 inactive domain-

TGME49_22

containing protein

7948
TGME49_23

173

peroxiredoxin PRX3 (PRX3)

174

phosphatidylinositol 3- and 4-kinase

175

phosphatidylinositol 3- and 4-kinase

176

phosphatidylserine decarboxylase

177

178

179

180

0410
TGME49_26
6010
TGME49_21
5700
TGME49_26
9920

phospholipase, patatin family

TGME49_21

protein

2130

phospholipase/carboxylesterase

TGME49_25
4690

proliferation-associated protein

TGME49_27

2G4, putative

9390

proteasome 26S regulatory subunit

TGME49_31

121

3410

40367

36

30

61439

45

45

51722

55

23

24909

35

18

56915

36

38

142762

34

74

30534

59

11

963722

35

519

316905

36

133

107987

34

79

109733

35

60

54235

33

29

50341

33

20

117708

42

82

Table A.2. (continued)
181

182

183

184

185

TGME49_23

protein kinase

9420

protein phosphatase 2C domain-

TGME49_20

containing protein

1630

protein phosphatase 2C domain-

TGME49_20

containing protein

1520

protein phosphatase 2C domain-

TGME49_23

containing protein

2340

protein phosphatase 2C domain-

TGME49_27

containing protein

0320
TGME49_25

186

Rad9 protein

187

RAP domain-containing protein

188

RAP domain-containing protein

189

5430
TGME49_23
9350
TGME49_23
7100

RecF/RecN/SMC N terminal

TGME49_25

domain-containing protein

7180

190

rhoptry neck protein RON5 (RON5)

191

rhoptry protein ROP16 (ROP16)

192

ribonuclease type III Dicer

193

ribosomal L37ae family protein

194

ribosomal protein RPL11 (RPL11)

TGME49_31
1470
TGME49_26
2730
TGME49_26
7030
TGME49_32
5400
TGME49_30

122

9820

183676

37

73

41457

32

31

42094

32

35

59867

83

31

58674

61

49

88589

35

53

297817

37

112

181991

38

99

181309

35

99

187408

33

103

76215

36

37

491971

39

171

13049

44

11

20199

52

10

Table A.2. (continued)
195

ribosomal protein RPL14 (RPL14)

196

ribosomal protein RPL17 (RPL17)

197

198

199

TGME49_26
7060
TGME49_29
9050

ribosomal protein RPL23A

TGME49_23

(RPL23A)

8010

ribosomal protein RPL3 (RPL3)

TGME49_22
7360

ribosomal protein RPL37A

TGME49_30

(RPL37A)

0190

200

ribosomal protein RPL4 (RPL4)

201

ribosomal protein RPL6 (RPL6)

202

ribosomal protein RPL7 (RPL7)

203

ribosomal protein RPP0 (RPP0)

204

ribosomal protein RPS10 (RPS10)

205

ribosomal protein RPS11 (RPS11)

206

ribosomal protein RPS17 (RPS17)

207

ribosomal protein RPS18 (RPS18)

208

ribosomal protein RPS2 (RPS2)

TGME49_30
9120
TGME49_31
3390
TGME49_31
4810
TGME49_21
8410
TGME49_27
5810
TGME49_22
6970
TGME49_20
7840
TGME49_22
5080
TGME49_30

123

5520

17878

40

13

22269

69

25

18561

37

24

44056

55

50

10404

44

20

49258

54

55

31222

111

23

30121

43

26

34157

75

27

17398

41

19

18677

41

20

15228

99

21

17722

46

13

29336

46

21

Table A.2. (continued)
209

ribosomal protein RPS20 (RPS20)

210

ribosomal protein RPS25 (RPS25)

211

ribosomal protein RPS26 (RPS26)

212

ribosomal protein RPS28 (RPS28)

213

ribosomal protein RPS4 (RPS4)

214

ribosomal protein RPS7 (RPS7)

215

ribosomal protein RPSA (RPSA)

216

217

218

219

220

221

222

TGME49_22
3050
TGME49_23
1140
TGME49_24
3570
TGME49_20
9290
TGME49_20
7440
TGME49_23
9100
TGME49_26
6060

ribosomal-ubiquitin protein

TGME49_24

RPS27A (RPS27A)

5620

RNA polymerase-associated protein TGME49_24
RTF1 (RTF1)

4210

RNA recognition motif-containing TGME49_32
protein

1500

RNA recognition motif-containing TGME49_21
protein

1420

RNA recognition motif-containing TGME49_32
protein

0100

RNA recognition motif-containing TGME49_26
protein

5250

RNA recognition motif-containing TGME49_26
protein

4610

124

25899

83

27

18682

46

9

12725

42

7

13214

61

11

35507

74

55

22587

47

19

31512

45

19

17321

53

15

84698

35

58

50938

40

57

20398

64

14

128921

32

105

160178

34

149

44974

37

26

Table A.2. (continued)
223

224

225

226

227

228

RNA recognition motif-containing TGME49_29
protein

1930
TGME49_21

rRNA pseudouridine synthase

4210

SAG-related sequence SRS14A

TGME49_25

(SRS14A)

4060

SAG-related sequence SRS29C

TGME49_23

(SRS29C)

3480
TGME49_24

Sec1 family protein

0740

site-specific recombinase, phage

TGME49_25

integrase family protein

9230

229

SNARE associated Golgi protein

230

STE kinase

231

subtilisin SUB2 (SUB2)

232

233

9370
TGME49_22
5960
TGME49_31
4500

surp module domain-containing

TGME49_24

protein

6500

sushi domain (scr repeat) domain- TGME49_22
containing protein

3480
TGME49_20

234

syntaxin protein

235

TBC domain-containing protein

236

TGME49_27

9820
TGME49_20
3910

T-complex protein 10 C-terminus

TGME49_25

protein

8710

125

73117

35

93

56744

43

45

40805

34

19

39119

83

17

71938

33

34

112628

34

88

46581

37

28

412543

36

171

141581

34

67

71701

34

36

507026

38

274

73624

38

39

228838

34

115

190704

35

108

Table A.2. (continued)
237

238

239

tetratricopeptide repeat-containing TGME49_30
protein

5150

tetratricopeptide repeat-containing TGME49_24
protein

2360

tetratricopeptide repeat-containing TGME49_24
protein

9480

240

Toxoplasma gondii family E protein

241

transmembrane protein

242

243

244

245

246

247

248

249

TGME49_24
0360
TGME49_31
3930

tRNA ligases class II (D, K and N) TGME49_22
domain-containing protein

0350

Tubulin-tyrosine ligase family

TGME49_22

protein

8410

UvrD/REP helicase domain-

TGME49_27

containing protein

7550
TGME49_25

Vps52 / Sac2 family protein

8832

V-type H(+)-translocating

TGME49_24

pyrophosphatase VP1

8670

WD domain, G-beta repeat-

TGME49_31

containing protein

5140

zinc finger (CCCH type) motif-

TGME49_25

containing protein

0690

zinc finger, C3HC4 type (RING

TGME49_21

finger) domain-containing protein

5640

153101

32

85

80215

33

46

126391

32

109

51331

39

49

94912

65

51

127446

36

63

125827

32

70

342488

33

124

86819

33

59

85295

35

25

155379

37

72

368046

34

161

160053

37

53
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